Media / Press Releases

Press Releases

Discover the latest news about our company, our products, our policies, and our people.

1287 Results

Date	Title
12 Jun 2019	Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
11 Jun 2019	FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children With Two Rare Blood Vessel Disorders
10 Jun 2019	FDA Grants Genentech’s Polivy Accelerated Approval for People With Previously Treated Aggressive Lymphoma
10 Jun 2019	Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
04 Jun 2019	Pivotal Phase III CLL14 Results for Venclexta in Combination With Gazyva for Chronic Lymphocytic Leukemia Presented at ASCO 2019 and Published in the New England Journal of Medicine
03 Jun 2019	Phase III Study Showed XOFLUZA (Baloxavir Marboxil) is Effective at Preventing Influenza Infection
02 Jun 2019	Xolair (omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults With Chronic Rhinosinusitis With Nasal Polyps in Two Phase III Studies
15 May 2019	Genentech Announces FDA Approval for Venclexta plus Gazyva for People With Previously Untreated Chronic Lymphocytic Leukemia
15 May 2019	Genentech’s Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, ROS1 Or ALK Gene Fusions in Children and Adolescents
09 May 2019	Genentech to Present New Data Highlighting Comprehensive Approach to Cancer Care at 2019 American Society Of Clinical Oncology (ASCO) Annual Meeting
07 May 2019	Genentech to Present New OCREVUS (ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Relapsing and Primary Progressive Multiple Sclerosis at the AAN Annual Meeting
06 May 2019	Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting
03 May 2019	FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
28 Apr 2019	New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
18 Mar 2019	FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
08 Mar 2019	FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
07 Mar 2019	Genentech Submits Supplemental New Drug Application to FDA for Venclexta Plus Gazyva for Previously Untreated Chronic Lymphocytic Leukemia with Co-Existing Medical Conditions
05 Mar 2019	FDA Accepts Genentech’s Supplemental New Drug Application for Xofluza (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications
28 Feb 2019	FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers
18 Feb 2019	FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma
18 Feb 2019	FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
04 Feb 2019	Genentech Submits Supplemental Biologics License Application to FDA For Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
29 Jan 2019	Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) - Other Company Programs in AD Continue
16 Jan 2019	FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
06 Dec 2018	FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
05 Dec 2018	Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
04 Dec 2018	FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer
03 Dec 2018	Genentech’s Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors
03 Dec 2018	New Venclexta® Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia
26 Nov 2018	FDA Approves The ACTpen For Genentech’s ACTEMRA, A Single-Dose, Prefilled Autoinjector For The Treatment Of Rheumatoid Arthritis, Giant Cell Arteritis And Two Forms Of Juvenile Arthritis
21 Nov 2018	Genentech Announces FDA Grants Venclexta Accelerated Approval for People With Newly-Diagnosed Acute Myeloid Leukemia or Those Who Are Ineligible For Intensive Induction Chemotherapy
12 Nov 2018	FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
01 Nov 2018	Genentech to Present New Data From Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting
31 Oct 2018	Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
27 Oct 2018	New STAIRWAY Study Data Shows Potential for Extended Durability With Faricimab in Wet Age-Related Macular Degeneration (AMD)
24 Oct 2018	Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza
22 Oct 2018	Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
21 Oct 2018	Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People With NTRK Fusion-Positive Solid Tumors
20 Oct 2018	Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
19 Oct 2018	FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
14 Oct 2018	Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
09 Oct 2018	OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
08 Oct 2018	Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and Across a Wide Range of Cancers at The European Society for Medical Oncology (ESMO) 2018 Congress
04 Oct 2018	FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
03 Oct 2018	Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
03 Oct 2018	Positive Phase III Results for Baloxavir Marboxil in People at High Risk of Complications From Influenza to be Presented at IDWeek 2018
01 Oct 2018	Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
28 Sep 2018	FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation
25 Sep 2018	Genentech’s TECENTRIQ in Combination With Chemotherapy Helped People Live Significantly Longer as an Initial Treatment for People With Extensive-Stage Small Cell Lung Cancer
24 Sep 2018	Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in a Type of Previously Untreated Advanced Lung Cancer
24 Sep 2018	Genentech’s Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer
13 Sep 2018	FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
05 Sep 2018	Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC)
29 Aug 2018	Positive Phase III Results for Genentech’s HEMLIBRA® (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine
12 Aug 2018	FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
25 Jul 2018	Genentech Unveils Positive Phase II Results for the Port Delivery System with Ranibizumab (PDS), the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
19 Jul 2018	Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)
18 Jul 2018	Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People With Advanced Lung Cancer
17 Jul 2018	FDA Grants Breakthrough Therapy Designation for Genentech’s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)
16 Jul 2018	Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu
11 Jul 2018	Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
01 Jul 2018	Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
25 Jun 2018	FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza
24 Jun 2018	Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy
13 Jun 2018	FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
13 Jun 2018	Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
08 Jun 2018	Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
07 Jun 2018	FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
04 Jun 2018	FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors
02 Jun 2018	Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer
28 May 2018	Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
20 May 2018	Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III Haven 3 Study in Hemophilia A Without Factor VIII Inhibitors
16 May 2018	Follow-Up Phase III Data Showed Genentech’s Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death
16 May 2018	Phase III IMpower150 Study Showed Genentech's TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel
14 May 2018	FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis
13 May 2018	Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress
09 May 2018	Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
07 May 2018	Genentech to Present New Data From Its Industry-Leading Oncology Portfolio at The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
06 May 2018	FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
22 Apr 2018	New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
16 Apr 2018	FDA Grants Breakthrough Therapy Designation For Genentech’s HEMLIBRA (emicizumab-kxwh) in Hemophilia A Without Inhibitors
15 Apr 2018	Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
25 Mar 2018	Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Carboplatin and Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared to Avastin Plus Carboplatin and Paclitaxel
21 Mar 2018	FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
19 Mar 2018	Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced The Risk of Disease Worsening or Death in the Initial Treatment of People With a Type of Advanced Squamous Lung Cancer
13 Feb 2018	FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
11 Feb 2018	Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
05 Feb 2018	Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People with Advanced Kidney Cancer
20 Dec 2017	FDA Approves Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer
12 Dec 2017	Genentech Announces Phase III Data Showing Venclexta plus Rituxan Reduced the Risk of Disease Progression or Death by 83 Percent Compared to a Standard of Care Regimen in Previously Treated Chronic Lymphocytic Leukemia
10 Dec 2017	Phase II Data Showed Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma
10 Dec 2017	Phase III IMmotion151 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
09 Dec 2017	Genentech’s HEMLIBRA (emicizumab-kxwh) Continued to Substantially Reduce Bleeds in People with Hemophilia A with Inhibitors
06 Dec 2017	Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
06 Dec 2017	Phase III IMpower150 Study Showed Tecentriq (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Reduced the Risk of Disease Worsening or Death by 38 Percent for People with a Type of Advanced Lung Cancer
05 Dec 2017	FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer
04 Dec 2017	First “Cancer Screen Week” Calls on Americans to Act Now Against Cancer by Taking Pledge to Get Screened
19 Nov 2017	Phase III IMpower150 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer
19 Nov 2017	Genentech’s Hemlibra (Emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
16 Nov 2017	FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A with Inhibitors
16 Nov 2017	FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
06 Nov 2017	FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
06 Nov 2017	FDA Approves Genentech’s Alecensa (Alectinib) as First-Line Treatment for People with Specific Type of Lung Cancer
01 Nov 2017	Genentech to Present New Data Across a Range of Blood Diseases at The American Society of Hematology (ASH) 2017 Annual Meeting
26 Oct 2017	New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
25 Oct 2017	FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer
15 Oct 2017	Genentech to Present New Ocrevus (Ocrelizumab) Efficacy & Safety Data in Relapsing and Primary Progressive Forms of Multiple Sclerosis at ECTRIMS
28 Sep 2017	FDA Grants Priority Review for Genentech’s Perjeta® (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer
18 Sep 2017	Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared to Bendamustine Plus Rituxan
08 Sep 2017	Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
06 Sep 2017	Genentech Issues Voluntary Nationwide Recall of Three Lots of Activase® (Alteplase)-100 mg Due to Lack of Sterility Assurance of the Sterile Water for Injection
30 Aug 2017	FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
27 Aug 2017	FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
23 Aug 2017	FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
07 Aug 2017	FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
02 Aug 2017	FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
26 Jul 2017	Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine
10 Jul 2017	Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
25 Jun 2017	Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors
22 Jun 2017	FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers
22 Jun 2017	New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
05 Jun 2017	APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-Positive Early Breast Cancer
05 Jun 2017	Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer
22 May 2017	FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
10 May 2017	Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
09 May 2017	Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
25 Apr 2017	New Data at AAN Reinforce Clinical Benefit of Genentech’s Ocrevus (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
18 Apr 2017	Genentech to Present New Data at AAN Reinforcing Efficacy And Safety of Newly FDA Approved Ocrevus (Ocrelizumab) in Two Types of Multiple Sclerosis
17 Apr 2017	FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
17 Apr 2017	FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States
16 Apr 2017	Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A
09 Apr 2017	Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer
29 Mar 2017	FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers
28 Mar 2017	FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
23 Mar 2017	FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
01 Mar 2017	Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy
17 Feb 2017	Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma
23 Jan 2017	FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis
08 Jan 2017	FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
05 Jan 2017	FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
21 Dec 2016	Positive Phase III Results of Genentech’s Investigational Medicine Ocrevus™ (Ocrelizumab) Published in New England Journal of Medicine
21 Dec 2016	Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
20 Dec 2016	FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
06 Dec 2016	FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
04 Dec 2016	Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer without their Disease Worsening Compared to Rituxan
12 Nov 2016	Phase III GiACTA Study Shows Genentech’s Actemra^® is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis
03 Nov 2016	Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
01 Nov 2016	Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
18 Oct 2016	FDA Approves Genentech’s Cancer Immunotherapy Tecentriq^® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer
14 Oct 2016	FDA Approves Genentech’s Lucentis^® (Ranibizumab Injection) Prefilled Syringe
10 Oct 2016	FDA Grants Priority Review to Genentech’s Lucentis^® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
08 Oct 2016	Genentech’s TECENTRIQ^® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy Regardless of PD-L1 Status in a Specific Type of Lung Cancer in Phase III Study
04 Oct 2016	FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
03 Oct 2016	FDA Grants Breakthrough Therapy Designation for Genentech’s Alecensa^® (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
13 Sep 2016	Phase III Efficacy Results of Investigational Medicine Ocrevus™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis
31 Aug 2016	Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQ^TM (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy
17 Jul 2016	Genentech Provides Update on Phase III Study of Gazyva® in People with Previously Untreated Diffuse Large B-Cell Lymphoma
07 Jul 2016	FDA Approves Genentech’s Xolair^® (omalizumab) for Allergic Asthma in Children
27 Jun 2016	FDA Grants Priority Review for Genentech’s OCREVUS™ (Ocrelizumab) Biologics License Application
05 Jun 2016	Genentech’s Cancer Immunotherapy Tecentriq™ (atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
05 Jun 2016	Phase III Study Shows Genentech’s Actemra^® (tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Arteritis (GCA)
26 May 2016	Genentech’s Gazyva^® Showed Superior Progression-Free Survival Compared to Rituxan^® in People with Previously Untreated Follicular Lymphoma
18 May 2016	FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer
18 May 2016	Phase III Study of Genentech’s Alecensa^® (alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People with a Specific Type of Lung Cancer
02 May 2016	Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
12 Apr 2016	Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis
11 Apr 2016	Genentech Announces FDA Grants Venclexta^™ (Venetoclax) Accelerated Approval for People with a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
10 Apr 2016	FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
14 Mar 2016	FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer
01 Mar 2016	FDA Files Genentech’s Supplemental Biologics License Application of Xolair^® (omalizumab) for Pediatric Allergic Asthma
28 Feb 2016	Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma
26 Feb 2016	FDA Approves Genentech’s Gazyva (Obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
16 Feb 2016	FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
12 Jan 2016	FDA Grants Priority Review for Venetoclax New Drug Application
11 Dec 2015	FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer
06 Dec 2015	Pivotal Phase II Study Showed Nearly 80 Percent of People with Hard-to-treat Type of Chronic Lymphocytic Leukemia Responded to Investigational Medicine Venetoclax
05 Dec 2015	New Results from CLL11 Study Show Gazyva® Provided People with Previously Untreated Chronic Lymphocytic Leukemia a Treatment-free Period of Nearly Four Years
21 Nov 2015	Updated Data Showed That Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) Helped People With a Specific Type of Advanced Melanoma Live Significantly Longer Than With Zelboraf Alone
10 Nov 2015	FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma
05 Nov 2015	Genentech to Present New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2015 Annual Meeting
08 Oct 2015	Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
27 Sep 2015	Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study
26 Sep 2015	Genentech Presents Positive Results from Pivotal Study of Investigational Immunotherapy Atezolizumab in Specific Type of Advanced Bladder Cancer at 2015 European Cancer Congress
26 Sep 2015	Two Positive Studies of Genentech’s Investigational Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer Presented at 2015 European Cancer Congress
08 Sep 2015	FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
07 Sep 2015	Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress
03 Sep 2015	U.S. FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
16 Aug 2015	Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer
12 Aug 2015	Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
12 Jul 2015	In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer
29 Jun 2015	Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
10 Jun 2015	FDA Grants Breakthrough Therapy Designation for Actemra (tocilizumab) in Systemic Sclerosis
31 May 2015	Genentech’s Perjeta Regimen Helped People with HER2-Positive Early Breast Cancer Live Longer without Their Disease Returning or Getting Worse Compared to Herceptin and Chemotherapy
30 May 2015	Genentech’s Gazyva® Extended the Time People with Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease Worsening
30 May 2015	Updated Data Showed Genentech’s Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening
13 May 2015	Genentech’s Investigational Immunotherapy MPDL3280A Reduced the Risk of Death by Half Compared with Chemotherapy in People with a Specific Type of Lung Cancer
13 May 2015	Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People with Specific Type of Lung Cancer
10 May 2015	Pivotal Data for Genentech Medicines in Lung and Blood Cancers To Be Presented at ASCO
04 May 2015	Genentech Announces New STEM Education Initiative to Support South San Francisco Schools
26 Mar 2015	Genentech Announces Plans To Expand Hillsboro Facility
18 Feb 2015	FDA Grants Genentech's Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
06 Feb 2015	FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema
03 Feb 2015	Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
01 Feb 2015	FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (anti-PDL1) in Non-Small Cell Lung Cancer
24 Dec 2014	FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chronic Lymphocytic Leukemia
18 Dec 2014	Genentech Provides Update on Phase III MARIANNE Study in People with Previously Untreated Advanced HER2-Positive Breast Cancer
14 Dec 2014	Genentech Submits New Drug Application to FDA for Investigational Cobimetinib Used in Combination with Zelboraf (vemurafenib) in Advanced Melanoma
05 Dec 2014	Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting
14 Nov 2014	FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy to Treat Women with Platinum-Resistant Recurrent Ovarian Cancer
15 Oct 2014	FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States
08 Oct 2014	FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Retinopathy
29 Sep 2014	Genentech’s Investigational Combination of Cobimetinib Plus Zelboraf (Vemurafenib) Provided Significant Benefit to People With Advanced Melanoma Over Zelboraf Alone
28 Sep 2014	Genentech’s Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic Breast Cancer By 15.7 Months Compared to Herceptin and Chemotherapy
14 Aug 2014	FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
08 Aug 2014	Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy
21 Jul 2014	FDA Grants Genentech’s Avastin Priority Review For Recurrent Platinum-resistant Ovarian Cancer
14 Jul 2014	FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
13 Jul 2014	Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer without their Disease Worsening
01 Jul 2014	Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
31 May 2014	Investigational Immunotherapy Anti-PDL1 (MPDL3280A) Shrank Tumors in 43 Percent of People With a Specific Type of Metastatic Bladder Cancer in a Genentech Study
13 May 2014	Genentech to Present New Data on 27 Different Medicines at ASCO
21 Mar 2014	FDA Approves Xolair® (omalizumab) for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
02 Mar 2014	Genentech Provides Update On Phase III Study Of Onartuzumab in People With Specific Type of Lung Cancer
07 Nov 2013	Genentech’s Gazyva Helped People with One of the Most Common Forms of Blood Cancer Live Significantly Longer without Their Disease Worsening Compared to Rituxan in Phase III CLL11 Study
01 Nov 2013	FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
21 Oct 2013	Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis
13 Oct 2013	Genentech Announces Plans to Expand California Biologics Manufacturing Facilities
10 Oct 2013	FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)
30 Sep 2013	FDA Grants Genentech’s Perjeta Accelerated Approval for Use Before Surgery in People With HER2-Positive Early Stage Breast Cancer
27 Sep 2013	Genentech’s Kadcyla Helped People With Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening in New Phase III Study
12 Sep 2013	FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer
09 Sep 2013	Genentech Executive Vice President Wins Lasker Award
23 Jul 2013	Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer Than Rituxan^® in People with One of the Most Common Forms of Blood Cancer
02 Jul 2013	FDA Grants Genentech's Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
01 Jul 2013	FDA Grants Genentech's Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
02 Jun 2013	Genentech's Medicine Avastin Plus Chemotherapy Improved Survival in Women with Advanced Cervical Cancer, Compared to Chemotherapy Alone
01 Jun 2013	Genentech Announces Final Phase III Study Results of Avastin Plus Radiotherapy and Chemotherapy in People with an Aggressive Form of Brain Cancer
15 May 2013	Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer
14 May 2013	FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer
14 May 2013	Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
30 Apr 2013	FDA Approves ACTEMRA^® for Children Living with a Rare Form of Arthritis
24 Feb 2013	Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic form of Hives who Failed Standard Therapy
22 Feb 2013	FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer
30 Jan 2013	Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People With Chronic Lymphocytic Leukemia (CLL)
23 Jan 2013	FDA Approves New Use of Avastin Plus Chemotherapy for People with Metastatic Colorectal Cancer
21 Dec 2012	Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants
07 Dec 2012	Genentech's Perjeta Significantly Extends Survival in People With HER2-Positive Metastatic Breast Cancer
17 Nov 2012	Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer without Their Disease Worsening When Added to Radiation and Chemotherapy
10 Nov 2012	ADACTA Study Showed ACTEMRA Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a Single-Agent Therapy
06 Nov 2012	FDA Grants Genentech's Trastuzumab Emtansine (T-DM1) Priority Review for HER2-Positive Metastatic Breast Cancer
12 Oct 2012	FDA Approves Expanded Indication for ACTEMRA^® in Rheumatoid Arthritis
01 Oct 2012	Genentech's Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
26 Aug 2012	New Data from Phase III EMILIA Study Showed Genentech's Trastuzumab Emtansine (T-DM1) Significantly Improved Survival of People With HER2-Positive Metastatic Breast Cancer
10 Aug 2012	FDA Approves Lucentis^® (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)
09 Aug 2012	Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease Worsening
26 Jul 2012	Genentech Reports Second Positive Study of ACTEMRA® Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis
26 Jul 2012	FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
21 Jun 2012	New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech's Perjeta
08 Jun 2012	FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
05 Jun 2012	Genentech's ACTEMRA^® Improved Rheumatoid Arthritis Signs and Symptoms Significantly More Than Adalimumab as Single-Agent Therapy
02 Jun 2012	Genentech's Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III Trial
02 Jun 2012	Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus Chemotherapy
01 Jun 2012	Genentech Study Showed That Adding Avastin to Chemotherapy Cut the Risk of the Disease Getting Worse in Difficult-to-Treat Recurrent Ovarian Cancer by Half
15 May 2012	Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
02 May 2012	Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
29 Mar 2012	Genentech's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
01 Mar 2012	Genentech's ACTEMRA® Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
07 Feb 2012	FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer
30 Jan 2012	FDA Approves Erivedge (Vismodegib) Capsule, the First Medicine for Adults with Advanced Basal Cell Carcinoma
13 Jan 2012	Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery Lucentis
07 Dec 2011	Genentech Announces Positive Results of Pivotal Phase III Study with Pertuzumab in HER2-Positive Metastatic Breast Cancer
29 Nov 2011	Genentech to Present Important New Data for HER2-Positive Breast Cancer at 2011 San Antonio Breast Cancer Symposium
18 Nov 2011	FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
08 Nov 2011	FDA Accepts Genentech's New Drug Application For Vismodegib in Advanced Form of Skin Cancer
05 Nov 2011	Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
19 Oct 2011	Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
24 Sep 2011	Genentech's Investigational Medicine T-DM1 Showed Improvement in Progression-Free Survival Compared to Standard of Care in HER2-Positive Metastatic Breast Cancer
12 Sep 2011	Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer
17 Aug 2011	FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
14 Jul 2011	Pertuzumab Combined with Herceptin and Chemotherapy Significantly Extended the Time People with HER2-Positive Metastatic Breast Cancer Lived without Their Disease Getting Worse
29 Jun 2011	Genentech Provides Update from FDA Hearing on Avastin for Metastatic Breast Cancer
28 Jun 2011	Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced Retinopathy
19 Jun 2011	Pivotal Study Showed Vismodegib Helped Shrink Tumors or Heal Lesions in People with Rare Form of Advanced Skin Cancer
05 Jun 2011	Genentech Announces Vemurafenib Improved Survival in People With Metastatic Melanoma Who Have BRAF V600 Mutations
04 Jun 2011	Genentech Announces Data to Show Avastin-Based Regimen Halved the Risk of Disease Getting Worse in Women with Recurrent Ovarian Cancer
02 Jun 2011	Tarceva Nearly Doubled the Time People with a Genetically Distinct Type of Lung Cancer Lived without Their Disease Getting Worse
18 May 2011	MetMAb in Combination with Tarceva Doubled the Time People with Lung Cancer Lived without Their Disease Getting Worse
17 May 2011	Genentech to Present Significant Progress in Advanced Skin, Lung and Ovarian Cancers at ASCO
10 May 2011	New Drug Applications Submitted in the United States and Europe for Vemurafenib in Advanced Skin Cancer
19 Apr 2011	FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
15 Apr 2011	FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
25 Mar 2011	Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
20 Mar 2011	Genentech Announces Positive Pivotal Phase II Results for Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma
10 Mar 2011	Phase III Study of Lucentis Showed Rapid Vision Improvements Sustained for Two Years in Patients with Diabetic Macular Edema
24 Feb 2011	FDA Grants Genentech a Hearing on Avastin's Use for Metastatic Breast Cancer in the United States
11 Feb 2011	Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema (DME)
07 Feb 2011	Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
28 Jan 2011	FDA Approves Rituxan for First-Line Maintenance Use in Follicular Lymphoma
27 Jan 2011	Early Successful Readout of Tarceva Study in a Distinct Form of Lung Cancer
18 Jan 2011	Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
13 Jan 2011	Genentech Informs Customers of Important Information About Triad Group's Alcohol Prep Pads
05 Jan 2011	FDA Grants Supplemental Approval for ACTEMRA® (tocilizumab)
16 Dec 2010	Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
10 Dec 2010	Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women with Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
05 Dec 2010	Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer
05 Dec 2010	Phase II Study with First-in-Class Investigational Drug Demonstrates Improvement in Negative Symptoms in Patients with Schizophrenia
07 Nov 2010	ACTEMRA Data Presented at ACR Annual Meeting on Rapid Response and Long-Term Efficacy in People with Rheumatoid Arthritis
04 Nov 2010	Genentech Reports Promising Phase II Results With New Targeted Approach in Advanced Melanoma
20 Oct 2010	FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
15 Oct 2010	Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
17 Sep 2010	Genentech Provides Update on Avastin for Advanced Breast Cancer
26 Aug 2010	Genentech Provides Update on FDA Application for T-DM1
10 Aug 2010	FDA Approves Longer Use of Valcyte for Adult Kidney Transplant Patients at High Risk of Developing Cytomegalovirus (CMV) Disease
20 Jul 2010	Genentech Provides Update From Avastin FDA Advisory Committee Meeting
06 Jul 2010	Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
01 Jul 2010	Second Phase III Study Showed Avastin-Containing Regimen Helped Women with Ovarian Cancer Live Longer Without their Disease Getting Worse
22 Jun 2010	FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion
06 Jun 2010	Phase III Study Showed Avastin-Based Regimen Helped Women with Advanced Ovarian Cancer Live Longer Without Their Disease Worsening
03 Jun 2010	Genentech's Scheller Wins Kavli Prize in Neuroscience
20 May 2010	Roche and Genentech to Present New Data on Different Approaches to Treating Cancer at ASCO
20 May 2010	Phase III Study Showed First-Line Maintenance Use of Rituxan® Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening
22 Apr 2010	Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
16 Apr 2010	FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
16 Mar 2010	Genentech Submits Supplemental Biologics License Application for ACTEMRA (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
11 Mar 2010	Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
24 Feb 2010	Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
22 Feb 2010	Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
18 Feb 2010	FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
15 Jan 2010	FDA Extends Review Period for Tarceva Application for First-line Maintenance Use in Advanced Non-small Cell Lung Cancer
08 Jan 2010	FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
16 Dec 2009	FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
12 Dec 2009	New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
11 Dec 2009	Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Women Previously Treated with Chemotherapy for Advanced Breast Cancer
10 Dec 2009	Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
07 Dec 2009	Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
18 Nov 2009	Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
16 Nov 2009	Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
17 Oct 2009	Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
17 Oct 2009	Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
04 Oct 2009	Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion
16 Sep 2009	Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
17 Aug 2009	Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
02 Aug 2009	FDA Approves Avastin for the Most Common Type of Kidney Cancer
30 Jul 2009	Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
28 Jul 2009	Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/Oncology
19 Jul 2009	Xeloda®-Oxaliplatin Combination (Xelox) Shown to Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer
12 Jul 2009	New Data from Phase III Saturn Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
02 Jul 2009	Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
30 May 2009	Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer
30 May 2009	Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy
29 May 2009	Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer
19 May 2009	Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
14 May 2009	Genentech to Present Advances With Targeted Cancer Medicines at ASCO
05 May 2009	FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
21 Apr 2009	Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
08 Apr 2009	Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
31 Mar 2009	FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)
26 Mar 2009	Roche Completes Acquisition of Genentech
18 Mar 2009	OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
12 Mar 2009	Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
11 Mar 2009	Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
06 Mar 2009	Genentech Urges Stockholders to Take No Action With Respect to Revised Offer From Roche
24 Feb 2009	Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding
23 Feb 2009	Genentech Special Committee Rejects Roche's $86.50 Offer as Inadequate
23 Feb 2009	Genentech Announces March 2, 2009 Webcast of Investment Community Meeting
19 Feb 2009	National Coalition for Cancer Survivorship, UCLA, Wellpoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
09 Feb 2009	Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer from Roche
02 Feb 2009	Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
30 Jan 2009	Special Committee of Genentech Board of Directors Responds to Roche's Announced Intention to Commence a Tender Offer
21 Jan 2009	Genentech Announces Vice President Appointment in Research
15 Jan 2009	Genentech Announces Full Year And Fourth Quarter 2008 Results
22 Dec 2008	Genentech Announces January 15 Webcast of Financial and Other Business Results
18 Dec 2008	Phase III Study Showed Rituxan Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)
06 Dec 2008	Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
23 Nov 2008	Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
17 Nov 2008	Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient
06 Nov 2008	Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
03 Nov 2008	Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
27 Oct 2008	Rituxan Data in Patients With Rheumatoid Arthritis To Be Presented at The American College of Rheumatology Annual Scientific Meeting
19 Oct 2008	Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
14 Oct 2008	Genentech Announces Third Quarter 2008 Results
06 Oct 2008	Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
05 Oct 2008	Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
02 Oct 2008	Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
02 Oct 2008	Genentech, Glycart and Roche Enter Into Collaboration Agreement for Potential Cancer Therapy
23 Sep 2008	Genentech Announces October 14 Webcast of Financial and Other Business Results
10 Sep 2008	Genentech Announces Vice President Appointment In Research
13 Aug 2008	Genentech Special Committee of Independent Directors Responds to Roche Proposal
24 Jul 2008	Genentech Forms Special Committee of Independent Directors to Review Roche Proposal
21 Jul 2008	Genentech Announces Receipt of Proposal From Roche
14 Jul 2008	Genentech Announces Second Quarter 2008 Results
23 Jun 2008	Genentech Announces July 14 Webcast of Financial and Other Business Results
11 Jun 2008	Genentech Settles Dispute Related To Cabilly Patent
31 May 2008	Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women With Advanced HER2-Negative Breast Cancer
19 May 2008	Genentech Announces June 2 Webcast Discussion of Data Presented at ASCO
15 May 2008	Genentech Provides Update on Avastin Program
15 May 2008	Genentech Provides Update On Studies Of Investigational Biooncology Agents To Be Presented At The American Society Of Clinical Oncology Meeting
29 Apr 2008	Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
24 Apr 2008	Genentech Announces Decision In Contract Dispute
20 Apr 2008	Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
15 Apr 2008	Genentech Extends Stock Repurchase Program
14 Apr 2008	Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
10 Apr 2008	Genentech Announces First Quarter 2008 Results
21 Mar 2008	Genentech Announces April 10 Webcast of Financial and Other Business Results
14 Mar 2008	Genentech Provides Business Update At Annual Investment Community Meeting
03 Mar 2008	Genentech Announces March 14 Webcast of Investment Community Meeting
25 Feb 2008	Genentech Receives Notification of Rejection of Cabilly Patent Claims From Reexamination Process
22 Feb 2008	FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
12 Feb 2008	Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer
24 Jan 2008	Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients With Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
14 Jan 2008	Genentech Announces Full Year and Fourth Quarter 2007 Results
20 Dec 2007	Genentech Announces January 14 Webcast Discussion of Financial and Other Business Results
05 Dec 2007	Genentech Provides Update From Avastin FDA Advisory Meeting
20 Nov 2007	Genentech Foundation for Biomedical Sciences Awards Nearly $1.2 Million to Health Science Education Programs in the Bay Area
18 Nov 2007	Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
15 Oct 2007	Genentech Announces Third Quarter 2007 Results
24 Sep 2007	Genentech Announces October 15 Webcast Discussion of Earnings and Other Business Results
24 Aug 2007	Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
02 Aug 2007	Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox
11 Jul 2007	Genentech Announces Second Quarter 2007 Results
26 Jun 2007	Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
20 Jun 2007	Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
04 Jun 2007	Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
03 Jun 2007	Genentech Provides Update on Pipeline Agents at The American Society of Clinical Oncology Meeting
02 Jun 2007	Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
02 Jun 2007	Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer
11 May 2007	Genentech Announces June 4 Webcast Discussion of Data Presented at ASCO
01 May 2007	Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
20 Apr 2007	Genentech Extends Stock Repurchase Program
11 Apr 2007	Genentech Announces First Quarter 2007 Results
23 Mar 2007	Genentech to Provide Business Update at Annual Investment Community Meeting
21 Mar 2007	Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
09 Mar 2007	Genentech Announces March 23 Webcast of Investment Community Meeting
21 Feb 2007	Analysis of International Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
21 Feb 2007	Genentech Provides Update on Cabilly Patent Reexamination
14 Feb 2007	Genentech Announces Additional Effort to Support Patient Access
02 Feb 2007	Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
29 Jan 2007	Genentech and Tanox Receive "Second Request" from the Federal Trade Commission
17 Jan 2007	Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations
10 Jan 2007	Genentech Announces Full Year and Fourth Quarter 2006 Results
08 Jan 2007	Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
08 Jan 2007	Genentech Again Named One of FORTUNE's "100 Best Companies to Work For"
04 Jan 2007	Genentech Announces Positive Results from a Randomized Phase II Study of Pertuzumab in Combination with Gemcitabine for Advanced Ovarian Cancer
20 Dec 2006	Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
14 Dec 2006	Key Herceptin Data Presented at San Antonio Breast Cancer Symposium
13 Dec 2006	New England Journal of Medicine Publishes Data From Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
11 Dec 2006	Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
16 Nov 2006	FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
11 Nov 2006	Subsequent Course of Rituxan Improved Outcomes in Rheumatoid Arthritis Patients Who Inadequately Responded to TNF Antagonist Therapy
09 Nov 2006	Genentech Announces Agreement to Acquire Tanox for $20 Per Share
07 Nov 2006	Genentech Announces Manufacturing Agreements With Lonza
11 Oct 2006	FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
10 Oct 2006	Genentech Announces Third Quarter 2006 Results
04 Oct 2006	Genentech Announces Vice President Appointments in Commercial Operations and Manufacturing
04 Oct 2006	New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
03 Oct 2006	Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications
29 Sep 2006	FDA Approves Two New Indications for Rituxan in Patients With Non-Hodgkin's Lymphoma
19 Sep 2006	Genentech Announces October 10 Webcast Discussion of Third Quarter Earnings and Other Business Results
11 Sep 2006	Genentech Receives Complete Response Letter From FDA for Avastin in Metastatic Breast Cancer
28 Aug 2006	Genentech and Biogen Idec Announce Positive Results from a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
17 Aug 2006	Genentech Foundation for Biomedical Sciences Awards $1.2 Million to Health Science Education Programs in the Bay Area
11 Aug 2006	Genentech Provides Update On Supplemental Biologics License Application For Adjuvant Herceptin In Early-Stage Her2-Positive Breast Cancer
26 Jul 2006	Genentech Announces Vice President and Officer Appointments in Product Development and Finance
25 Jul 2006	Genentech & Inotek Enter into Exclusive Global Strategic Alliance for the Discovery, Development and Commercialization of PARP Inhibitors for Cancer
11 Jul 2006	Genentech Announces Second Quarter 2006 Results
30 Jun 2006	FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
26 Jun 2006	Phase III Study of Avastin in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
22 Jun 2006	Analysis of Phase III Study Showed Rituxan Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
20 Jun 2006	Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
20 Jun 2006	FDA Approves Avastin in Combination with Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
05 Jun 2006	Results From a Randomized Phase II Trial Suggested the Combinations of Avastin Plus Tarceva and Avastin Plus Chemotherapy Improved Progression-Free Survival in Advanced Non-Small Cell Lung Cancer
02 Jun 2006	Preliminary Results from a Phase IIIb Study Showed Patients with Wet AMD Treated with Lucentis Quarterly Experienced a 16-Letter Benefit over the Control Group at One Year
25 May 2006	Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line Metastatic Breast Cancer
22 May 2006	Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
22 May 2006	Genentech Announces June 5 Webcast Discussion of Data Presented at ASCO
19 May 2006	Genentech Announces June 2 Webcast Discussion Of Lucentis Data Presented At The 2006 Retinal Physician Symposium
11 May 2006	Genentech Announces Vice President Appointments In Commercial Operations And Product Development
21 Apr 2006	Genentech Extends Stock Repurchase Program
11 Apr 2006	Genentech Announces First Quarter 2006 Results
11 Apr 2006	Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
10 Apr 2006	Genentech Announces Vice President Appointments in Commercial Operations and Product Development
30 Mar 2006	Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
23 Mar 2006	Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
17 Mar 2006	Genentech Provides Updates at Annual Investment Meeting
03 Mar 2006	Genentech Announces March 17 Webcast of Investment Community Meeting
28 Feb 2006	FDA Approves Rituxan - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
28 Feb 2006	Genentech Granted Six-Month Priority Review for Lucentis for the Treatment of Wet Age-Related Macular Degeneration
15 Feb 2006	Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin in Early-Stage HER2-Positive Breast Cancer
12 Feb 2006	Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
10 Feb 2006	FDA Approves Rituxan Plus CHOP or other Anthracycline-Based Chemotherapy Regimens for First-Line Treatment of Diffuse Large B-Cell Non-Hodgkin's Lymphoma
26 Jan 2006	Amgen and Genentech Sign License Agreements for Antibody Patents
14 Jan 2006	Preliminary Phase III Data from Head-to-Head Study of Lucentis Shows Lucentis Improved Vision Compared to Visudyne in Patients with Wet Age-Related Macular Degeneration
10 Jan 2006	Genentech Announces Full Year and Fourth Quarter 2005 Results
09 Jan 2006	Genentech Announces Vice President Appointments in Commercial Operations, Corporate Information Technology, Product Development and Product Operations
09 Jan 2006	Genentech Named Number 1 on FORTUNE's 100 Best Companies to Work For
06 Jan 2006	Genentech Announces January 14th Webcast Discussion Of Data Presented At Macula 2006 Meeting
05 Jan 2006	Genentech Announces Executive Promotions
30 Dec 2005	Genentech Submits Biologics License Application for FDA Review of Lucentis in Wet Age-Related Macular Degeneration
21 Dec 2005	Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
19 Dec 2005	Genentech Submits Supplemental Biologics License Application for Avastin in Relapsed Metastatic Colorectal Cancer
10 Nov 2005	Biogen Idec and Genentech Announce November 16th Webcast Discussion of Rituxan Data Presented at ACR
07 Nov 2005	Preliminary Data from Phase III Trial Show Lucentis is the First Investigational Therapy to Demonstrate Clinical Benefit over Visudyne in a Head-to-Head Study of Patients with Wet AMD
02 Nov 2005	FDA Approves Tarceva in Combination with Gemcitabine Chemotherapy for Treatment of Locally Advanced, Inoperable or Metastatic Pancreatic Cancer
31 Oct 2005	Biogen Idec and Genentech Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for Rituxan in Rheumatoid Arthritis
25 Oct 2005	FDA Grants Priorty Review for Rituxan Supplemental Biologics License Application for Front-Line Treatment of Intermediate-Grade or Aggressive Non-Hodgkin's Lymphoma
19 Oct 2005	Pivotal Herceptin Data in the New England Journal of Medicine Showed Significant Improvement in Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
19 Oct 2005	Genentech and ABC2 Announce Second Brain Cancer Collaboration
18 Oct 2005	Genentech Announces Preliminary Results from Randomized Phase II Trial of Avastin and Tarceva in Kidney Cancer
10 Oct 2005	Genentech Announces Third Quarter 2005 Results
27 Sep 2005	Genentech Provides Information on Patent Reexamination
23 Sep 2005	Genentech Provides Update on Phase II Study with Avastin in Platinum-Refractory Ovarian Cancer
19 Sep 2005	Genentech Announces October 10 Webcast Discussion of Earnings and Other Business Results
13 Sep 2005	Fourth Phase III Study Shows Herceptin Plus Chemotherapy Improved Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
13 Sep 2005	FDA Advisory Panel Recommends Tarceva Approval for Pancreatic Cancer
07 Sep 2005	Genentech Announces Plans to File for FDA Approval of Lucentis for the Treatment of Wet Age-Related Macular Degeneration in December
31 Aug 2005	Biogen Idec and Genentech Submit a Supplemental Biologics License Application for FDA Review of Rituxan for the Treatment of Rheumatoid Arthritis
17 Aug 2005	Genentech and Biogen Idec File Supplemental Biologics License Application for FDA Review of Rituxan for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-Positive, B-Cell, Non-Hodgkin's Lymphoma
16 Aug 2005	Genentech Announces Organizational Changes
29 Jul 2005	Genentech Foundation for Biomedical Sciences Bolsters Innovation in Health Science Education with $1.2 Million for Bay Area Programs
18 Jul 2005	Phase III Study Shows Lucentis Improved Vision in Patients With Wet Age-Related Macular Degeneration
18 Jul 2005	Preliminary Phase I/II Study Showed Lucentis Improved Vision in Patients with Wet Age-Related Macular Degeneration When Used in Combination with Visudyne
13 Jul 2005	Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
13 Jul 2005	Genentech Announces Intention to Offer up to $2 Billion in Senior Notes
13 Jul 2005	Genentech Announces Pricing of $2 Billion in Senior Notes
11 Jul 2005	Genentech Announces Second Quarter 2005 Results
05 Jul 2005	Genentech Announces July 18 Webcast Discussion of Data Presented at ASRS
28 Jun 2005	Genentech Announces Vice President Appointments in Product Operations, Regulatory, and Research
24 Jun 2005	Genentech Provides Manufacturing Update
23 Jun 2005	Genentech Announces June 24 Webcast Discussion of Recent Manufacturing Activities
20 Jun 2005	Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
16 Jun 2005	Biologics Manufacturing Facility to be Purchased by Genentech from Biogen Idec
15 Jun 2005	Genentech Extends Share Repurchase Program
09 Jun 2005	Preliminary Phase IIb Study Showed Rituxan Improved Symptoms in Rheumatoid Arthritis Patients Who Failed One or More Disease-Modifying Anti-Rheumatic Drugs
31 May 2005	Preliminary Phase I/II Data Show Lucentis in Combination With Visudyne Maintained or Improved Vision in Approximately 90 Percent of Patients With Wet Age-Related Macular Degeneration
23 May 2005	Preliminary Phase III Data Show Lucentis Maintained or Improved Vision in Nearly 95 Percent of Patients with Wet Age-Related Macular Degeneration
15 May 2005	Data From Omnitarg Clinical Program Presented at American Society of Clinical Oncology Meeting
14 May 2005	Phase III Study of Tarceva in Combination with Chemotherapy Improves Survival in Pancreatic Cancer Patients
13 May 2005	Phase III Trial of Avastin Plus Chemotherapy Showed 30 Percent Improvement in Overall Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
13 May 2005	Avastin Plus Chemotherapy Showed Doubling of Time Without Cancer Progression in Phase III Trial of First-Line Metastatic Breast Cancer Patients
13 May 2005	Herceptin Plus Chemotherapy Improved Disease-Free Survival and Overall Survival in Adjuvant Setting for Early-Stage Her2-Positive Breast Cancer Patients
04 May 2005	Genentech Announces Vice President Appointments in Product Operations and Product Development
04 May 2005	Genentech Announces Webcast Discussions of Data Presented at ASCO; Phase III Breast Cancer Studies to be Presented at Educational Session
02 May 2005	OSI Pharmaceuticals and Genentech Announce Filing of a Supplemental New Drug Application to the FDA for Tarceva in Pancreatic Cancer
25 Apr 2005	Interim Analysis of Phase III Studies Shows Herceptin Plus Chemotherapy Improves Disease-Free Survival in the Adjuvant Setting for Early-Stage HER2-Positive Breast Cancer Patients
14 Apr 2005	Interim Analysis of Phase III Trial Shows Avastin Plus Chemotherapy Improved Progression-Free Survival in Patients with First-Line Metastatic Breast Cancer
11 Apr 2005	Genentech Announces First Quarter 2005 Results
05 Apr 2005	Phase III Study Shows Rituxan Significantly Improves Symptoms in Patients with Rheumatoid Arthritis Who Inadequately Responded to Anti-TNF Therapies
21 Mar 2005	Genentech and Ipsen Agree to Develop Sustained-Release Formulations of Recombinant Human Growth Hormone
21 Mar 2005	Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
14 Mar 2005	Interim Analysis of Phase III Trial Shows Avastin Plus Chemotherapy Extends Survival of Patients with First-Line Non-Squamous, Non-Small Cell Lung Cancer
04 Mar 2005	Genentech Announces Strategic Updates at Investment Meeting
25 Feb 2005	Genentech Announces March 4 Webcast of Investment Community Meeting
18 Feb 2005	Three-Year Study with Raptiva Showed Long-Term and Sustained Clearing in Moderate-to-Severe Plaque Psoriasis Patients
27 Jan 2005	Preliminary Positive Results from Phase III Trial of Avastin Plus FOLFOX4 Chemotherapy Presented at ASCO GI Meeting
27 Jan 2005	Data From Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients
10 Jan 2005	Genentech Again Named One of FORTUNE's "100 Best Companies To Work For"
10 Jan 2005	Genentech Announces Fourth Quarter and Full Year 2004 Results
06 Jan 2005	Genentech Finalizes Avastin Label with Previously Announced Safety Information
22 Dec 2004	Genentech Board Announces Executive Promotions and Senior Appointments in Commercial Operations, Finance and Manufacturing
21 Dec 2004	Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
29 Nov 2004	Phase III Results Show Avastin Plus Folfox4 Chemotherapy Significantly Extend Survival in Second-Line Metastatic Colorectal Cancer
25 Nov 2004	Genentech Again Named the No. 1 Employer in Science Magazine Survey
18 Nov 2004	FDA Approves Tarceva for Patients with Advanced Non-Small Cell Lung Cancer
18 Nov 2004	Genentech Announces November 18 Webcast Discussion of Tarceva FDA Approval
10 Nov 2004	Genentech Announces Organizational Changes
09 Nov 2004	Genentech and Rinat Neuroscience Announce Co-Development and Joint Commercialization Agreement for Anti-NGF Antibody for Acute and Chronic Pain
04 Nov 2004	Genentech Announces Senior Appointments in Manufacturing and Engineering
01 Nov 2004	Preliminary Phase IIb Data Show Rituxan Improved Symptoms in Patients with Moderate-to-Severe Rheumatoid Arthritis
21 Oct 2004	Genentech to Seek Review of Court Decision in Contract Dispute
06 Oct 2004	Genentech Announces Third Quarter 2004 Results
04 Oct 2004	Genentech Receives Subpoena on Rituxan
28 Sep 2004	Genentech Extends Share Repurchase Program
23 Sep 2004	Genentech and Wyeth Announce Manufacturing Agreement
20 Sep 2004	Tarceva Plus Gemcitabine Improves Survival Compared to Gemcitabine Alone in First-Line Pancreatic Cancer Patients
15 Sep 2004	Genentech Announces October 6 Webcast Discussion of Earnings and Other Business Results
10 Sep 2004	Genentech and OSI Pharmaceuticals Initiate Phase IIIB Clinical Trial of Tarceva in Advanced Non-Small Cell Lung Cancer
02 Sep 2004	Giants and Genentech Devote Sunday, September 5 to Striking Out Cancer
10 Aug 2004	Genentech Announces FDA Approval of Avastin Manufacturing at Vacaville Facility
02 Aug 2004	OSI Pharmaceuticals and Genentech Announce Completion of New Drug Application for FDA Approval of Tarceva
29 Jul 2004	Preliminary Data Showed Sustained Clinical Benefit for Moderate-to-Severe Plaque Psoriasis Patients Treated with Raptiva for 30 Months
07 Jul 2004	Genentech Announces Second Quarter 2004 Results
30 Jun 2004	Genentech Announces Senior Appointments in Commercial Operations and Development
17 Jun 2004	Genentech Announces July 7 Webcast Discussion of Earnings and Other Business Results
16 Jun 2004	OSI Pharmaceuticals and Genentech Enter into Co-Promotion and Manufacturing Agreements for Tarceva
16 Jun 2004	Positive Data from Preliminary Phase II Study of Rituxan in Rheumatoid Arthritis Published in the New England Journal Of Medicine
08 Jun 2004	Genentech Presents Data from Broad Avastin Clinical Trial Program at the American Society of Clinical Oncology Meeting
07 Jun 2004	Key Herceptin Data Presented at American Society of Clinical Oncology Meeting
05 Jun 2004	Preliminary Phase III Data Showed Front-Line Use of Rituxan Plus Chemotherapy Improved Survival in Patients Under 60 with Aggressive Non-Hodgkin's Lymphoma
05 Jun 2004	Preliminary Results of a Phase III Study Showed Rituxan Maintenance Therapy Improved Progression-Free Survival in Newly Diagnosed Patients with Indolent Non-Hodgkin's Lymphoma
05 Jun 2004	Early Clinical Data Evaluating the Combination of Avastin and Tarceva Yield Initial Promising Results in Several Cancers
05 Jun 2004	Phase III Study of Tarceva in Relapsed Non-Small Cell Lung Cancer Shows Significant Improvement in Survival
02 Jun 2004	Pivotal Avastin Study in New England Journal of Medicine Showed Significant Improvement in Patients with Metastatic Colorectal Cancer
01 Jun 2004	Genentech and Alkermes Announce Decision to Discontinue Commercialization of Nutropin Depot
21 May 2004	Genentech Announces Webcast Discussions of Data Presented at ASCO
18 May 2004	Genentech Foundation for Biomedical Sciences Awards More Than $1 Million to Science Education Programs in the Bay Area
25 Apr 2004	Tarceva Extends Survival of Patients with Relapsed Non-Small Cell Lung Cancer
16 Apr 2004	Genentech Announces Approval of Two-for-One Stock Split
07 Apr 2004	Genentech Announces First Quarter 2004 Results - Increase of 28 Percent in Product Sales
06 Apr 2004	Genentech Win in Chiron Patent Litigation Unanimously Affirmed by U.S. Court of Appeals
24 Mar 2004	Genentech Announces Senior Appointment in Corporate Information Technology
21 Mar 2004	Genentech and XOMA Announce Results of Phase II Study of Raptiva in Psoriatic Arthritis Patients
12 Mar 2004	Genentech Announces Long-Term Strategy and Financial Goals
10 Mar 2004	Genentech Announces April 7 Webcast Discussion of Earnings and Other Business Results
09 Mar 2004	Genentech Announces Organizational Changes
03 Mar 2004	Genentech's Board of Directors Approves a Conditional Stock Split
02 Mar 2004	Genentech Announces March 12 Webcast of Investment Community Meeting
26 Feb 2004	Genentech, Novartis and Tanox Settle Disputes Surrounding Xolair and TNX-901
26 Feb 2004	FDA Approves Avastin, a Targeted Therapy for First-Line Metastatic Colorectal Cancer Patients
16 Jan 2004	Genentech Announces Senior Appointments in Development, Commercial and Manufacturing
14 Jan 2004	Genentech Reports $3.3 Billion in Revenues with $1.9 Billion in Oncology Sales
07 Jan 2004	Genentech Announces Webcast of Presentation at JP Morgan 22nd Annual Healthcare Conference
29 Dec 2003	Genentech Named Number 15 on Fortune's "Best Companies To Work For" List
15 Dec 2003	Genentech Announces January 14 Webcast Discussion of Earnings and Other Business Results
15 Dec 2003	Genentech and Lonza Announce Manufacturing Agreement
08 Dec 2003	Initial Results of a Randomized Phase II Study Suggest that Rituxan Maintenance Therapy Prolongs Remission in Indolent NHL
07 Dec 2003	Initial Data from Phase III ECOG 4494 Study of Rituxan as Front-Line and Maintenance Therapy in Aggressive Non-Hodgkin's Lymphoma (NHL) Presented at ASH
07 Dec 2003	Initial Results of a New Study of Rituxan Plus CVP Chemotherapy Demonstrate Prolonged Time to Treatment Failure as Front-Line Therapy for Patients with Indolent Non-Hodgkin's Lymphoma
07 Dec 2003	Phase III Trial of Rituxan Plus Chemotherapy as a Front-Line Therapy in Aggressive Non-Hodgkin's Lymphoma Reaches Pre-Specified Efficacy Endpoint Two Years Early
05 Dec 2003	Genentech Announces Share Repurchase Program
04 Dec 2003	Preliminary Results of a Phase II Study of Herceptin and Taxotere (docetaxel) Combination Suggests Improved Survival in HER2-Positive Metastatic Breast Cancer Patients
01 Dec 2003	Genentech Announces FDA Acceptance of Biologics License Application with Priority Review of Avastin In First-Line Metastatic Colorectal Cancer
25 Nov 2003	Genentech Reports Results from Phase II Trial of Avastin in Metastatic Colorectal Cancer
24 Nov 2003	Genentech Announces December 7th Webcast Discussion of Data Presented at ASH
19 Nov 2003	Study in New England Journal of Medicine Shows Extending Raptiva (efalizumab) Treatment Provides Rapid and Continuous Benefit
13 Nov 2003	Eastern Cooperative Oncology Group (ECOG) Phase III Trial of Rituxan Maintenance Therapy in Indolent Non-Hodgkin's Lymphoma Reaches Pre-Specified Efficacy Endpoint Early
11 Nov 2003	Boehringer Ingelheim and Genentech Announce Initiation of a Clinical Trial Evaluating TNKase/Metalyse Use Prior to Angioplasty for Treatment of Heart Attack
10 Nov 2003	Genentech Named to "Scientific American 50" List
04 Nov 2003	Initial Data Released From Phase III ECOG 4494 Study of Rituxan as Front-Line and Maintenance Therapy in Aggressive Non-Hodgkin's Lymphoma
27 Oct 2003	FDA Approves Raptiva (efalizumab) for Chronic Moderate-to-Severe Plaque Psoriasis
26 Oct 2003	Follow-Up Data from Phase II Study of Rituxan as a Potential Treatment for Rheumatoid Arthritis Show Durability of Response at 48 Weeks
23 Oct 2003	Genentech Named the No. 1 Rated Employer in Science Magazine Survey
08 Oct 2003	Genentech Reports 17 Percent Increase in Non-GAAP Earnings Per Share for Third Quarter 2003
07 Oct 2003	Genentech Announces Senior Appointments in Commercial Operations and Research
01 Oct 2003	Phase III Trials of Tarceva(TM) Plus Chemotherapy in First-Line Non-Small Cell Lung Cancer Do Not Meet Primary Efficacy Endpoint
29 Sep 2003	Genentech Files Biologics License Application for FDA Approval of Avastin in First-Line Metastatic Colorectal Cancer
24 Sep 2003	Genentech Announces October 8 Webcast Discussion of Earnings and Other Business Results
09 Sep 2003	FDA Advisory Committee Unanimously Recommends Approval for Raptiva as a Potential Treatment for Moderate-to-Severe Plaque Psoriasis
03 Sep 2003	Genentech Appoints Marc Tessier-Lavigne to Senior Vice President, Research Drug Discovery
03 Sep 2003	Genentech Promotes Richard Scheller to Executive Vice President, Research
02 Sep 2003	Genentech Announces September 9th Webcast Discussion of DODAC Review of Raptiva BLA
27 Aug 2003	Genentech and Amgen Settle Patent Dispute
18 Aug 2003	Genentech Presents Positive Preliminary Six-Month Data from Phase Ib/II Study for Lucentis in Age-Related Macular Degeneration (AMD)
08 Aug 2003	Tarceva (erlotinib HCl) Phase II Clinical Trial Initiated in Patients with Malignant Glioma
31 Jul 2003	Genentech and XOMA Announce FDA Advisory Committee Review of Raptiva
26 Jul 2003	New Data Support Raptiva as a Potential Long-Term Treatment for Moderate-to-Severe Plaque Psoriasis
17 Jul 2003	Genentech Announces Senior Appointments in Research and Commercial Operations
09 Jul 2003	Genentech Reports 35 Percent Increase in Non-GAAP Earnings Per Share for Second Quarter
26 Jun 2003	Genentech Receives FDA Fast-Track Designation for Avastin
25 Jun 2003	Genentech Announces July 9 Webcast Discussion of Earnings and Other Business Results
24 Jun 2003	Genentech and Novartis Ophthalmics Announce Development and Commercialization Agreement for Age-Related Macular Degeneration Treatment, Lucentis
20 Jun 2003	FDA Approves Xolair, Biotechnology Breakthrough for Asthma
20 Jun 2003	Genentech and IDEC Announce Humanized Anti-CD20 Antibody Development Collaboration
17 Jun 2003	Genentech and Biogen Announce Autoimmune Collaboration
02 Jun 2003	Clinical Data from Phase II Study in Early Breast Cancer Suggest Potential Use of Herceptin with New Chemotherapy Combination
01 Jun 2003	Genentech Reports Additional Data from BioOncology Pipeline at ASCO
01 Jun 2003	Positive Results from Phase III Avastin Study in Metastatic Colorectal Cancer Presented at ASCO
31 May 2003	Preliminary Positive Data From Rituxan Multi-Center Trial in First-Line and Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia (CLL)
31 May 2003	Tarceva (erlotinib HCl) Shows Encouraging Safety Profile and Activity in Phase I Clinical Study in Patients with Malignant Glioma
29 May 2003	Genentech Names Corsee Sanders Vice President, Biometrics and Business Operations, Medical Affairs
23 May 2003	Genentech Announces June 1st Webcast Discussion of Data Presented at ASCO
19 May 2003	Phase III Trial of Avastin Plus Chemotherapy Markedly Extends Survival of Metastatic Colorectal Cancer Patients
15 May 2003	FDA Advisory Committee Unanimously Recommends Approval of Xolair
12 May 2003	Genentech and XOMA Discontinue Rheumatoid Arthritis Trial
08 May 2003	Genentech And ABC(2) Agree to Collaborate on Brain Cancer Clinical Trial
08 May 2003	Genentech Announces May 15th Webcast Discussion of PADAC Review of Xolair BLA
16 Apr 2003	Genentech Announces April 23 Webcast of Annual Meeting of Stockholders
10 Apr 2003	Genentech Foundation for Biomedical Sciences Awards $1 Million to Science Education Programs in the Bay Area
09 Apr 2003	Genentech Reports 59 Percent Increase in Non-GAAP Earnings Per Share for First Quarter
27 Mar 2003	Genentech, Novartis and Tanox Announce FDA Advisory Committee Review of Xolair (Omalizumab)
26 Mar 2003	Genentech Announces April 9 Webcast Discussion of Earnings and Other Business Results
22 Mar 2003	Preliminary Results from Open-Label Raptiva Study Suggest Continued Benefit with Long-Term Treatment
21 Mar 2003	Phase III Study Results with Raptiva in the Treatment of Psoriasis Presented at Annual AAD Meeting
14 Mar 2003	Genentech Projects Double-Digit Growth for 2005-2010
12 Mar 2003	Genentech Appoints Philippa Norman Vice President, Global Supply Chain
07 Mar 2003	Genentech Announces March 21 Webcast Discussion of Data Presented at the American Academy of Dermatology
03 Mar 2003	Genentech Announces March 14 Webcast of Investment Community Meeting
27 Jan 2003	Genentech Appoints Ian Clark Senior Vice President and General Manager, BioOncology
15 Jan 2003	Genentech Exceeds $2.7 Billion in Revenues with $1.5 Billion in Oncology Sales
06 Jan 2003	Genentech Named One of Fortune's "100 Best Companies To Work For"
06 Jan 2003	Genentech Announces Webcast of Presentation at JP Morgan 21st Annual Healthcare Conference
02 Jan 2003	Genentech Announces January 15 Webcast Discussion of Earnings and Other Business Results
23 Dec 2002	Genentech and XOMA Submit Biologics License Application for FDA Approval of Raptiva(TM) (Efalizumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis
18 Dec 2002	Genentech and Novartis Submit Amendment to the Biologics License Application for Xolair (TM) (Omalizumab) to FDA
11 Dec 2002	Preliminary Results from Phase III Study Demonstrate Herceptin/Chemotherapy Combination Delays Time to Disease Progression in HER2-Positive Breast Cancer
09 Dec 2002	Investigational Data Demonstrate Potential of Extended Rituxan(R) Use to Increase Event-Free Survival in Patients with Indolent NHL
20 Nov 2002	Pre-Hospital Thrombolytic Treatment of Heart Attack Found Feasible and Faster Than In-Hospital Therapy
28 Oct 2002	Preliminary Positive Data from Investigational Randomized Phase II Trial Demonstrates Rituxan as a Potential Treatment for Rheumatoid Arthritis
09 Oct 2002	Genentech Reports 23 Percent Increase in Product Sales for Third Quarter
07 Oct 2002	Genentech Announces Senior Appointments in Medical Affairs and Research
01 Oct 2002	Genentech Announces Preliminary Positive Phase Ib/II Data for rhuFab V2 in Age-Related Macular Degeneration (AMD)
26 Sep 2002	Genentech Announces October 9 Webcast Discussion of Earnings and Other Business Results
24 Sep 2002	Genentech Recognized as One of The 100 Best Companies for Working Mothers
19 Sep 2002	Genentech Listed as Top Employer in Science Survey
17 Sep 2002	Genentech and XOMA Announce Phase III Study with Raptiva(TM) Achieves Primary Efficacy Endpoint
09 Sep 2002	Phase III Trial With Avastin(TM) in Relapsed Metastatic Breast Cancer Does Not Meet Primary Endpoint
06 Sep 2002	Genentech Wins Patent Dispute With Chiron
04 Sep 2002	Genentech Names Stephen G. Juelsgaard Executive Vice President
29 Aug 2002	Genentech Receives FDA Approval to Include HER2 Gene Detection Test in Herceptin(R) Product Labeling
19 Aug 2002	Genentech Extends Stock Repurchase Program
19 Aug 2002	OSI Pharmaceuticals and Genentech Provide Update on Status of Tarceva Program
15 Aug 2002	U.S. PTO Interference Declared in Genentech/Chiron Patent Dispute
07 Aug 2002	Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva
02 Aug 2002	Genentech and XOMA Announce Preliminary Data from Long-Term Study with Investigational Psoriasis Therapy
01 Aug 2002	Tarceva U.S. Phase III Non-Small Cell Lung Cancer Clinical Trial Completes Patient Enrollment
10 Jul 2002	Genentech Reports 28 Percent Increase in Product Sales for Second Quarter
24 Jun 2002	Genentech to Appeal Judgment in Contract Dispute
20 Jun 2002	Genentech Announces July 10 Webcast Discussion of Earnings and Other Business Results
18 Jun 2002	Preliminary Data from Phase II Study of Rituxan for Rheumatoid Arthritis are Positive
17 Jun 2002	Investigational Data from Randomized Study of Extended Therapy with Rituxan(R) Demonstrates Potential to Delay Disease Progression in Patients with Indolent NHL
10 Jun 2002	Genentech Announces Verdict in Contract Dispute
21 May 2002	Investigational Data Demonstrates Potential Use of Rituxan in Various CD20-Positive Cancers
20 May 2002	National Cancer Institute (NCI) Study Demonstrates Genentech's Investigational Anti-Angiogenesis Treatment Avastin(TM) Delays Time to Disease Progression in Metastatic Kidney Cancer
14 May 2002	Genentech and OSI Pharmaceuticals Announce FDA Fast-Track Designation for Tarceva(tm)
14 May 2002	Genentech Appoints Hal Barron Vice President, Medical Affairs
09 May 2002	Genentech Invites Investors to Listen to Webcast of May 21 Discussion of ASCO Presentations
23 Apr 2002	FDA Approves Nutropin AQ PEN (TM) For Delivery Of Nutropin AQ (R) Recombinant Growth Hormone
22 Apr 2002	Genentech Foundation for Biomedical Sciences Awards $869,411 to Support Quality Science Education in the Bay Area
09 Apr 2002	Genentech Reports 22 Percent Increase in Product Sales For First Quarter
05 Apr 2002	Genentech and Xoma Obtain Results from Xanelim(TM) (Efalizumab) Pharmacokinetic Study
25 Mar 2002	Genentech Announces April 9 Webcast Discussion of Earnings and Other Business Results
05 Mar 2002	Genentech Names Gene Murano Vice President, Regulatory Affairs
25 Feb 2002	Genentech to Collaborate with ABC2 for Brain Cancer Research
25 Feb 2002	Xanelim (Efalizumab) Study Results Presented at 60th Annual American Academy of Dermatology Meeting
06 Feb 2002	Phase III Tracleer (bosentan) Study in Chronic Heart Failure Does Not Meet Primary Efficacy Objective
28 Jan 2002	Genentech Names Mark Ahn Vice President, Hematology Sales and Marketing
23 Jan 2002	New England Journal of Medicine Study Shows 53 Percent Increase in Event-Free Survival in Patients Treated with Rituxan and CHOP Chemotherapy
21 Jan 2002	Genentech Named One of Fortune's "100 Best Companies To Work For"
16 Jan 2002	Genentech Exceeds $2 Billion in Revenues with $1 Billion in Oncology Sales
20 Dec 2001	Genentech Announces January 16 Webcast Discussion of Earnings and Other Business Results
18 Dec 2001	Genentech Granted Fundamental U.S. Patent for Antibody Technology
12 Dec 2001	Genentech Receives FDA Approval to Add Survival Data to Herceptin Product Labeling
10 Dec 2001	Investigational Data Presented on Use of Rituxan in the Treatment of Immune Thrombocytopenic Purpura (ITP)
10 Dec 2001	Potential Extended Survival Benefit Shown with Rituxan and Chop Chemotherapy Study as Front-Line Therapy in Common Forms of Non-Hodgkin's Lymphoma (NHL)
10 Dec 2001	Clinical Trial Data Presented on Rituxan with Chemotherapy as Front-Line Treatment in Chronic Lymphocytic Leukemia (CLL)
07 Dec 2001	Key Milestones Achieved in Genentech's Biooncology Initiative
05 Dec 2001	FDA Advisory Committee Unanimously Recommends Approval of Breast Cancer Test to Select Candidates for Herceptin Therapy
30 Nov 2001	Genentech Invites Public to Listen to Webcast of December 10 Discussion of Rituxan Presentations at the American Society of Hematology Meeting
08 Nov 2001	Genentech Announces Stock Repurchase Program
07 Nov 2001	Genentech Announces Four Senior Appointments in Development and Product Operations
01 Nov 2001	Genentech and Novartis Update Xolair BLA Amendment Timeline
25 Oct 2001	National Cancer Institute (NCI) Trial Studying Genentech's Avastin in Advanced Kidney Cancer Reaches Pre-Specified Efficacy Endpoint Early
24 Oct 2001	No Verdict Reached in Genentech, City of Hope Contract Dispute
10 Oct 2001	Genentech Reports 34 Percent Increase in Product Sales for Third Quarter
09 Oct 2001	Genentech Named Among 100 Best Companies for Working Mothers
04 Oct 2001	Genentech and Xoma Update Xanelim BLA Filing Timing
26 Sep 2001	Genentech Announces October 10 Webcast Discussion of Earnings and Other Business Results
04 Sep 2001	FDA Approves Cathflo™ Activase® (Alteplase) To Restore Function To Central Venous Access Devices As Assessed By The Ability To Withdraw Blood
23 Aug 2001	ASSENT 3 Trial Shows Heart Attack Patients May Benefit From New Treatment Regimen: Clot-Buster Plus Low-Molecular-Weight Heparin
06 Aug 2001	Genentech Appoints Andrew C. Chan to Senior Director of Immunology
30 Jul 2001	Xanelim Shows Initial Positive Results in Second Pivotal Phase III Study
23 Jul 2001	Genentech Invites Public to Listen to Webcast of July 31 Discussion of Xanelim Phase III Results
16 Jul 2001	Genentech Foundation for Biomedical Sciences Awards $766,000 to Local Community Programs
11 Jul 2001	Genentech Reports 33 Percent Increase in Product Sales for Second Quarter
10 Jul 2001	FDA Issues Complete Response Letter for Xolair (Omalizumab)
28 Jun 2001	Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
21 Jun 2001	Xanelim in Pivotal Phase III Study Shows Initial Positive Results
14 Jun 2001	Genentech Invites Public to Listen to Webcast of June 21 Discussion of Xanelim Phase III Results
07 Jun 2001	Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech
30 May 2001	Genentech Names Thomas T. Thomas Treasurer
24 May 2001	Phase III Clinical Trials of Xanelim Humanized Monoclonal Antibody for Moderate-to-Severe Psoriasis Show Preliminary Positive Results
15 May 2001	Positive Investigational Data Presented On Rituxan Plus Fludarabine As Potential Front-Line Therapy For Chronic Lymphocytic Leukemia
15 May 2001	Genentech Appoints David Ebersman Senior Vice President, Product Operations
14 May 2001	Addition of Herceptin to Chemotherapy Demonstrates 50 Percent increase in Survival Benefit in Patients Selected by FISH
14 May 2001	FDA Approves Expanded Use of Rituxan for Treatment of Low-Grade Non-Hodgkin's Lymphoma (NHL)
14 May 2001	OSI Pharmaceuticals, Genentech and Roche Announce Clinical Data From Phase II Ovarian Cancer Trial of Tarceva (OSI-774)
12 May 2001	OSI Pharmaceuticals, Genentech and Roche Announce Interim Clinical Data From Phase II Cancer Studies of the Anti-EGFR Therapy Tarceva® (OSI-774)
04 May 2001	Genentech Wins Patent Dispute With GlaxoSmithKline
03 May 2001	Genentech Invites Public to View Webcast of May 10 Annual Meeting of Stockholders
01 May 2001	Oral Endothelin Receptor Antagonist Tracleer Meets Primary Endpoint In Pulmonary Arterial Hypertension Study
19 Apr 2001	Phase III Clinical Trial of Veletri for the Treatment of Acute Heart Failure Symptoms Does Not Meet Primary Efficacy Objective
12 Apr 2001	Genentech Reports 38 Percent Increase in Product Sales for First Quarter
10 Apr 2001	Genentech Appoints Kimberly Popovits Senior Vice President, Marketing and Sales, for CardioPulmonary and Specialty Markets
06 Apr 2001	Genentech and Biotech Celebrate 25 Years of Scientific and Medical Innovation
29 Mar 2001	Genentech Announces April 12 Webcast Discussion of Earnings and Other Business Results
20 Mar 2001	First Endothelin Receptor Antagonist Shows Positive Preliminary Results for Acute Heart Failure
16 Mar 2001	Genentech and Actelion Announce March 20 Webcast Discussion of Veletri (Tezosentan) RITZ-2 Trial Results
14 Mar 2001	Study Published in New England Journal of Medicine Demonstrates Herceptin with Chemotherapy Increases Median Survival in Women with Metastatic Breast Cancer
08 Mar 2001	Genentech And Novartis Update Expectations For FDA Review Of Xolair Biologics License Application
01 Mar 2001	Genentech Names Robert Garnick Senior Vice President, Regulatory, Quality And Compliance
13 Feb 2001	Genentech Invites Public to Listen to February 21, 2001 Webcast
12 Feb 2001	Phase III Trial of Intravenous Endothelin Receptor Antagonist Tezosentan for Acute Heart Failure Shows Positive Hemodynamic Results
18 Jan 2001	Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000
11 Jan 2001	Genentech Names John Whiting Vice President
09 Jan 2001	Genentech Announces January 18 Webcast Discussion of Earnings and Other Business Results
08 Jan 2001	OSI Pharmaceuticals, Genentech and Roche Team up to Deveolp and Commercialize OSI-774, OSI's Leading Cancer Drug to Develop and Commercialize OSI-774, OSI's Lead Cancer Drug
08 Jan 2001	COR, Schering-Plough, and Genentech Announce U.S. Collaboration for INTEGRILIN® (eptifibatide) Injection, TNKase^TM (Tenecteplase) and Activase® (Alteplase, Recombinant)
08 Jan 2001	Genentech and Alkermes to Expand Clinical Development of Nutropin Depot™
03 Jan 2001	Names Richard H. Scheller Senior Vice President, Research
19 Dec 2000	Genentech Names Claudia Estrin Vice President, Decision Support and Commercial Innovation
18 Dec 2000	Genentech Named One Of Fortune's "100 Best Companies To Work For In America"
12 Dec 2000	Actelion and Genentech Sign Licensing Agreement for Tracleer™ (Bosentan) in the U.S.
08 Dec 2000	Phase III Trials Underway Evaluating Herceptin In Early Stage Breast Cancer
05 Dec 2000	New Investigational Data Presented on Rituxan Plus Chemotherapy as Potential Front-Line Therapy
04 Dec 2000	Potential Survival Benefit Shown with Rituximab and CHOP Chemotherapy in Aggressive Non-Hodgkin's Lymphoma
11 Oct 2000	Genentech Reports 25 Percent Increase in Product Sales for Third Quarter
05 Oct 2000	Genentech Announces 2-For-1 Stock Split Effective October 17
02 Oct 2000	Genentech Announces Filing of Supplemental Biologic License Application
26 Sep 2000	Genentech Appoints Nagler to Vice President of Human Resources
11 Sep 2000	Genentech Launches Annual Community Relations Program to Boost Local Economic Development
08 Aug 2000	Genentech Appoints Joseph S. McCracken Vice President, Business Development
17 Jul 2000	Genentech Reports 15 Percent Increase in Product Sales for Second Quarter
13 Jul 2000	Genentech CEO Says Amgen/TKT Trial Outcome Not a Bellwether for Biotech
16 Jun 2000	Genentech Announces Phase II Trial of Experimental Anti-CD18 Antibody Did Not Meet Its Primary Objectives
05 Jun 2000	Genentech and Novartis Submit Application for FDA Approval of Anti-IgE Antibody
02 Jun 2000	FDA Approves New, Single-Injection Clot Buster TNKase (Tenecteplase) For Treatment Of Heart Attack
25 May 2000	Genentech Appoints Andrew Scherer Vice President, Engineering and Facilities
23 May 2000	Single Agent Herceptin Demonstrates 26 Percent Response Rate as Front-Line Metastatic Breast Cancer Therapy in Phase II Trial
23 May 2000	Preliminary Positive Phase II Results for Experimental Anti-VEGF Monoclonal Antibody with Chemotherapy in Lung Cancer Presented at ASCO
21 May 2000	Anti-VEGF Monoclonal Antibody with Chemotherapy Demonstrates Preliminary Positive Phase II Results in Colorectal Cancer
18 May 2000	Genentech Names Roy C. Hardiman Vice President, Corporate Law
16 May 2000	Genentech Appoints Myrtle Potter to EVP of Commercial Operations and COO
08 May 2000	ImmunoGen and Genentech Form Multi-Product Collaboration to Develop Tumor-Activated Prodrugs
04 May 2000	ImmunoGen and Genentech Sign Exclusive License Agreement
01 May 2000	Immunex and Genentech Moving Forward with Preclinical Development Program of TRAIL/Apo2L
25 Apr 2000	Genentech's Vacaville Facility Granted FDA Licensure
12 Apr 2000	Genentech Reports 21 Percent Increase in Product Sales for First Quarter
06 Apr 2000	Genentech Appoints Kraines Vice President of Finance
06 Apr 2000	Genentech Purchases Cell Culture Manufacturing Facility in Spain
23 Mar 2000	Offering by Roche of 17.3 Million Genentech Shares Priced at $163 Per Share
15 Mar 2000	Roche to Launch Offering of Up to 19 Million Genentech Shares
13 Mar 2000	Genentech Issues Important Drug Notification for Pulmozyme Due to Packing Defect
13 Mar 2000	Genentech Announces Clinical Trials Testing TNKase (Tenecteplase) with Leading Anti-Thrombotics for Treatment of Heart Attack
04 Mar 2000	Studies Show Investigational Compound May Help Improve Control of Asthma Exacerbations While Reducing the Need for Steroids and Rescue Medication
15 Feb 2000	Actelion and Genentech Sign Licensing Agreement for Tezosentan in the U.S.
20 Jan 2000	Genentech Reports 1999 Year-End Results
18 Jan 2000	Genentech to File Motion and Appeal to Maintain Injunction Against BTG
12 Jan 2000	Roche to Issue Exchangeable Bonds
23 Dec 1999	FDA Approves Nutropin Depot(TM), First Long-Acting Dosage Form of Recombinant Growth Hormone for Growth Hormone Deficiency in Children
21 Dec 1999	Genentech and Inspire to Collaborate on Respiratory Therapeutics
20 Dec 1999	Genentech and XOMA Announce Initiation of Anti-CD11A Phase III Clinical Trials for Psoriasis
20 Dec 1999	Genentech Named One of Fortune's "100 Best Companies to Work for in America"
17 Dec 1999	Phase III Anti-IgE Asthma Clinical Trials Show Positive Preliminary Results
16 Dec 1999	Genentech to Proceed With Phase III Trials of Experimental Anti-Angiogenesis Monoclonal Antibody
04 Dec 1999	New Data from Key Rituxan Clinical Studies Presented at 41st Annual Society of Hematology Meeting
02 Dec 1999	FDA Approves Efficacy Results for Spine Bone Mineral Density in Childhood-Onset Growth Hormone Deficient Adults
19 Nov 1999	University of California and Genentech Settle Patent Infringement Lawsuits
09 Nov 1999	COR Therapeutics, Schering-Plough and Genentech Announce Plans to Study INTEGRILIN -- eptifibatide -- Injection in Combination with TNKase -- tenecteplase -- in Heart Attack Patients
08 Nov 1999	Genentech and IDEC Pharmaceuticals to Receive 1999 Trailblazers Award from Cure for Lymphoma Foundation
27 Oct 1999	Genentech and Chairman/CEO Levinson to Receive National Breast Cancer Coalition's Corporate Leadership Award
22 Oct 1999	Genentech 2-For-1 Stock Split Effective on October 29
20 Oct 1999	Secondary Offering by Roche of 20 Million Genentech Shares Priced at $143.50
08 Oct 1999	SEC Registration Filed for Genentech Public Offering
07 Oct 1999	Roche To Publicly Sell 20 Million Genentech Shares, Genentech Board Approves 2-For-1 Stock Split
29 Sep 1999	Genentech Chairman/CEO Arthur Levinson Receives Irvington Institute's Corporate Leadership Award
27 Sep 1999	Genentech Appoints Sulzbach Vice President, Information Resources
22 Sep 1999	Genentech Names Levinson as New Board Chair and Announces Appointment of Two New Directors
13 Sep 1999	Genentech Launches Annual Program to Boost Economic Development of Its Hometown of 23 Years
01 Sep 1999	Genentech Named Among 100 Best Companies For Working Mothers
24 Aug 1999	Genentech Appoints James Panek, Senior Vice President, Product Operations
24 Aug 1999	Genentech Appoints Laura Leber Vice President, Corporate Communications
19 Aug 1999	XOMA Announces Expansion of Genentech Collaboration in hu1124 to Include Organ Transplant Rejection
02 Aug 1999	Genentech Submits Application for FDA Approval of Tenecteplase (TNK-tPA)
19 Jul 1999	Genentech, Inc. Announces Public Offering of 20 Million Shares Under New NYSE Trading Symbol, DNA
12 Jul 1999	Genentech Reports 1999 Second Quarter Results
08 Jul 1999	Unique Program Allows Previous Genentech Shareholders to be Included in Genentech Public Offering
01 Jul 1999	Genentech Appoints Diane Parks Vice President of Marketing
30 Jun 1999	Genentech Scientists Receive Distinguished Inventor Award
28 Jun 1999	Genentech and Alkermes Announce the Submission of a New Drug Application with the FDA for Nutropin Depot
14 Jun 1999	Roche Exercises Option to Redeem Genentech Shares
14 Jun 1999	SEC Registration Filed for Genentech Public Offering
13 Jun 1999	Phase III Clinical Trial Shows Promising Results of Nutropin Depot
08 Jun 1999	Genentech and Immunex Announce Patent License Agreement for Immunoadhesin Technology for ENBREL
07 Jun 1999	Study Shows Simpler Procedures Employed by Industry-Sponsored Heart Attack Registry Are Comparable to More Complex Government Program
02 Jun 1999	Genentech to Remain Independent Company, Roche Intends to Exercise Its Call Option and Publicly Reissue Genentech Shares
02 Jun 1999	No Verdict Reached in Genentech, University of California Patent Infringement Case
01 Jun 1999	Immunex Corporation and Genentech, Inc. Join Forces To Develop TRAIL/Apo2L in Cancer
19 May 1999	Genentech Confirms Growth Hormone Research Performed Independently; Seeburg Testimony is False
15 May 1999	Follow-Up Data Shows Improvement in Overall Survival in Metastatic Breast Cancer Patients Treated with Herceptin, Plus Chemotherapy
14 May 1999	Phase III Trial with Anti-IgE Shows Positive Results in Treating Seasonal Allergic Rhinitis
15 Apr 1999	XOMA and Genentech Extend hu1124 (Anti-CD11a) Collaboration Through Phase III
14 Apr 1999	Genentech Confirms Settlement Agreement with U.S. Government
12 Apr 1999	Genentech Reports 1999 First Quarter Results
09 Apr 1999	Genentech Discussing Settlement with U.S. Government
08 Apr 1999	Phase III Trial With Nerve Growth Factor Did Not Reach Its Goal
09 Mar 1999	International Trial Shows Promising Results for Genentech's New Clot Buster Compared with Activase
22 Feb 1999	Genentech Names Ebersman Vice President
18 Feb 1999	Preliminary Phase II Trial Results with Experimental Vascular Endothelial Growth Factor in Patients with Coronary Artery Disease are Disappointing
09 Feb 1999	Genentech Issued New t-PA Patent and Files Patent Infringement Suit Against Centocor's Thrombolytic Agent
29 Jan 1999	Schwarz Pharma AG and Genentech enter into a collaboration for two growth hormone products
21 Jan 1999	Genentech Reports 41 Percent Increase in Year-End Net Income
12 Jan 1999	Genentech Corporate Child Care Center Celebrates 10 Years
21 Dec 1998	Genentech Named One of Fortune's 100 Best Companies to Work For in America
10 Dec 1998	Genentech Appoints Dilly Vice President of Medical Affairs
08 Dec 1998	Rituxan Follow-Up Data Shows 28 Percent of Responders Still in Remission
09 Nov 1998	New Investigational Data Show Monoclonal Antibody to IgE May Reduce Seasonal Allergy Symptoms
03 Nov 1998	Genentech Names Barta Vice President, Quality
23 Oct 1998	Genentech Dedicates $250 Million Vacaville Facility
22 Oct 1998	Genentech and Alkermes Announce Positive Preliminary Results of Phase III Clinical Trial of Nutropin Depot®
14 Oct 1998	Genentech Reports Third Quarter Results
25 Sep 1998	Biotechnology Breakthrough In Breast Cancer Wins FDA Approval
14 Sep 1998	Genentech and South San Francisco Celebrate Six-Year Anniversary of Community Program
02 Sep 1998	FDA Advisory Committee Recommends Approval of First Monoclonal Antibody for Metastatic Breast Cancer
17 Aug 1998	Pivotal Clinical Trial of First Monoclonal Antibody
20 Jul 1998	U.S. Stroke Study Halted Due to Lack of Clinical Benefit Observed in Patients Treated After Three Hours
14 Jul 1998	Genentech Reports 1998 2nd Quarter Results
06 Jul 1998	Roche And Genentech Sign Licensing Agreement For Herceptin
29 Jun 1998	Novo Nordisk and Genentech Settle Long Term Dispute over Patents
25 Jun 1998	Genentech Names Johnston Vice President, Intellectual Property
18 May 1998	Phase II Pilot Study of Rituxan with Chemotherapy Showed 97% Response Rate in Type of Non-Hodgkin's Lymphoma
18 May 1998	Genentech Names Moore Vice President of Government Affairs
18 May 1998	Results of Phase III Studies Announced for HER2 Antibody, Herceptin
05 May 1998	Genentech Names Dennis Henner and Stephen Juelsgaard to Senior Vice Presidents
04 May 1998	Genentech Submits Application for FDA Approval of HER2 Antibody, Herceptin
14 Apr 1998	Genentech Reports 1998 First Quarter Results - 30 Percent Earnings Increase
13 Apr 1998	Genentech Names Moore New Head of Government Affairs Office
31 Mar 1998	Genentech Receives Fast Track Product Designation for Herceptin By FDA
17 Mar 1998	Genentech Files Patent Infringement Suit Against Centocor's Thrombolytic Agent
02 Mar 1998	Pulmozyme Receives FDA Approval for Labeling Change
02 Mar 1998	Genentech and Dako Announce Collaboration on HER2 Diagnostic Kit In Breast Cancer
28 Jan 1998	Vice President Gore To Visit Genentech
22 Jan 1998	Genentech's Year-End Results On Track
08 Jan 1998	Sumitomo Pharmaceuticals and Genentech Enter Into Collaboration
08 Jan 1998	Pharmacia & Upjohn Acquires Rights from Genentech for Thrombopoietin (TPO)
19 Dec 1997	Genentech Announces Phase III Investigational Trial Results
18 Dec 1997	Genentech Wins FDA Clearance of its Ready-To-Use Nutropin AQ
18 Dec 1997	LeukoSite and Genentech Enter Collaboration
17 Dec 1997	Genentech Wins Clearance of Nutropin for Growth Hormone Deficiency
16 Dec 1997	New Drug for Non-Hodgkin's Lymphoma Available Now
04 Dec 1997	Alteon and Genentech to Collaborate on Therapy for Diabetic Complications
26 Nov 1997	First New Drug for Non-Hodgkin's Lymphoma in Decade Receives FDA Clearance for Marketing
24 Nov 1997	Genentech and Alkermes Announce Plans to Advance Prolease®, Human Growth Hormone to Phase III Clinical Trials
14 Oct 1997	Genentech Reports 1997 Third Quarter Results
19 Sep 1997	Anti-IgE Monoclonal Antibody Progresses to Phase III Trials in Asthma
05 Sep 1997	Genentech Discontinues IGF-I Drug Development Effort in Diabetes
04 Sep 1997	Health Care Pioneers Reinforce Commitment to Improving Public Health
26 Aug 1997	New Clot-Dissolving Agent Shows Promise
25 Jul 1997	FDA Advisory Committee Recommends Clearance for Cancer Treatment
15 Jul 1997	Genentech Reports 1997 Second Quarter Results
24 Jun 1997	Genentech Creates New Strand of DNA
16 Jun 1997	Genentech and South San Francisco Celebrate Community Program
15 May 1997	Genentech Focuses On Cancer as it Launches BioOncology Initiative
05 May 1997	Genentech Announces Plans to Study TNK-tPA in Phase III
01 May 1997	Genentech Appoints Lars Barfod Vice President of Marketing
15 Apr 1997	Genentech Reports 1997 First Quarter Results
09 Apr 1997	Genentech is Granted Patents for Recombinant Factor VIII
02 Apr 1997	Scios Suspends Development of AURICULIN
01 Apr 1997	FDA Clears Genentech's Nutropin AQ
20 Mar 1997	Bill Young Appointed COO of Genentech
19 Mar 1997	Leader in Oncology to Head Genentech's Molecular Oncology Department
17 Mar 1997	Comparison of Two Heart Attack Drugs Fails to Prove Primary Endpoint
07 Mar 1997	Genentech Appoints Two New Vice Presidents
03 Mar 1997	IDEC, Genentech & Roche Submit Applications for Approval of IDEC-C2B8
21 Jan 1997	Genentech Reports 1996 Year-End Results
09 Jan 1997	Roche and GNE Announce Agreement for Roferon-A
30 Dec 1996	FDA Clears Genentech's Nutropin Human Growth Hormone
13 Dec 1996	Genentech Names Dick Munro as New Board Chair
12 Dec 1996	Genentech Founder Swanson Retires as Board Chair
10 Dec 1996	FDA Advisory Committee Recommends Nutropin
09 Dec 1996	IDEC Pharmaceuticals and Genentech Announce Positive Final Results
03 Dec 1996	Genentech and Baxter to Collaborate
02 Dec 1996	Pulmozyme Receives Marketing Clearance for Use in Advanced Cystic Fibrosis Patients
21 Oct 1996	Genentech Reports 1996 Third Quarter Results
15 Oct 1996	Genentech Advances Study of Nerve Growth Factor
09 Oct 1996	FDA Advisory Committee Recommends Pulmozyme
30 Sep 1996	Genentech Files Amended Complaint Against Novo Nordisk
26 Sep 1996	Delaware Court Approves Settlement
15 Jul 1996	New Senior Vice Presidents
15 Jul 1996	Genentech Employees Take Another $50,000 Shopping Spree In Downtown South San Francisco, The Company's Hometown For 20 Years
15 Jul 1996	Genentech Reports 1996 Second Quarter Results
09 Jul 1996	Tanox Biosystems and Genentech Settle Lawsuits
27 Jun 1996	Genentech Granted Preliminary Injunction
18 Jun 1996	Activase Cleared by FDA for U.S. Marketing
07 Jun 1996	Genentech Discontinues Pursuit of Actimmune for Renal Cell Carcinoma
06 Jun 1996	FDA Advisory Committee Recommends Approval of Activase
28 May 1996	Patent Infringement Suit Filed Against Boehringer
23 May 1996	Genentech Donates $25,000 To Solano Community College
30 Apr 1996	Genentech Names Robert Arathoon to VP of Process Science
29 Apr 1996	Genentech Names Henner as Head of Research
22 Apr 1996	Genentech and XOMA Agree to Develop Jointly Anti-CD11a
16 Apr 1996	Genentech Reports 1996 First Quarter Results
08 Apr 1996	Appeals Court Upholds Preliminary Injunction Prohibiting Sales of Biotechnology General's Growth Hormone Product
04 Apr 1996	Biotechnology Pioneer Genentech Turns 20
04 Apr 1996	Genentech Licenses Worldwide Rights From Washington University for GDNF Homologue, Neurturin
02 Apr 1996	Genentech Wins Second Major Biotechnology Patent Dispute In Japan
19 Mar 1996	Genentech Submits Product License Application for Activase
20 Feb 1996	Genentech Names Cynthia Ladd VP, Corporate Law
20 Feb 1996	Genentech Announces Creation of Genenvax to Develop AIDS Vaccine
18 Jan 1996	Genentech Posts Strong Year-End Results
04 Jan 1996	Levinson Appoints McLaughlin and Young as Executive Vice Presidents
03 Jan 1996	FDA Grants Genentech Clearance to Market Nutropin AQ
18 Dec 1995	Patent Claims Upheld for Genentech's t-PA in Europe
17 Nov 1995	Brewer Resigns as Genentech's Senior VP of Sales & Marketing
25 Oct 1995	Genentech Stockholders Approve Roche's Extended Buyout Option
23 Oct 1995	Genentech Reports 20 Percent Increase in Earnings for Third Quarter 1995
05 Oct 1995	Genentech's Blood Platelet Factor (TPO) Enters the Clinic as Phase I Trial Begins
04 Oct 1995	Genentech Submits NDA for Nutropin in Turner's Syndrome
03 Oct 1995	Ed Jennings Cleared of All Charges
13 Sep 1995	Genentech Completes Negotiations, Purchases Land For New Manufacturing Facility in Vacaville, CA
21 Aug 1995	Genentech Receives Favorable Ruling on Process Patent Applicaiton for Recombinant Human Factor VIII:C
11 Aug 1995	Genentech Granted Preliminary Injunction Prohibiting Sale of Bio-Technology General (BTG) Human Growth Hormone Product
18 Jul 1995	Genentech Reports 1995 Second Quarter Results
10 Jul 1995	Review Board Recommends Termination of Phase III Study of Pulmozyme in Chronic Obstructive Pulmonary Disease
10 Jul 1995	Genentech Board Names Levinson President & CEO
28 Jun 1995	Judge Grants Genentech's Request for Preliminary Injunction Prohibiting Sale of Novo Nordisk's Growth Hormone
25 May 1995	Genentech and Roche Change Form of Transaction to Accommodate New Schedule for Stockholder Vote
12 Apr 1995	Genentech Reports Strong 1995 First Quarter Results
03 Apr 1995	Accelerated Infusion Regimen of Activase Cleared by FDA for U.S. Marketing
03 Mar 1995	Genentech and IDEC Pharmaceuticals to Collaborate on Anti-CD20 Monoclonal Antibody for B-Cell Lymphomas
19 Jan 1995	Genentech Reports 1994 Fourth Quarter Results
17 Jan 1995	ITC Votes Not to Review Judge's Decision
05 Jan 1995	Genentech and Lilly Reach Settlement
03 Jan 1995	Genentech and Scios Nova Enter Into Agreement for Development of Acute Kidney Failure Treatment
30 Nov 1994	Judge Finds Growth Hormone Patent Infringement by Novo-Nordisk and BTG; Recommends Dismissal of Complaint On Technicality
24 Nov 1994	Study Reaffirms Benefits of Activase t-PA
31 Oct 1994	Genentech Locates Major New Facility in Vacaville, CA
18 Oct 1994	Genentech Reports 1994 Third Quarter Results
12 Sep 1994	Genentech Names Louis J. Lavigne, Jr. Senior Vice President and Stephen Juelsgaard Vice President and General Counsel
25 Aug 1994	Genentech Names Dennis Henner and Bryan Lawlis Vice Presidents
05 Aug 1994	Genentech Opposes Recommendations to Make Growth Hormone a Scheduled Drug
04 Aug 1994	Genentech Employee Indicted on Charges of Violating Medicare/Medicaid Anti-Remuneration Laws as a Result of Federal Investigation in Minnesota
18 Jul 1994	Genentech Reports 1994 Second Quarter Results
28 Jun 1994	Genentech Responds to Ruling Regarding t-PA Patent Infringement by Genetics Institute
16 Jun 1994	Local Elementary School Students 'Go To Town' with Genentech Employees in South San Francisco
15 Jun 1994	Genentech Reports Discovery of New Blood Platelet Factor
10 Jun 1994	FDA's Cardio-Renal Advisory Committee Unanimously Recommends Accelerated Activase t-PA Label Change by FDA
07 Jun 1994	Genentech Names Polly Moore and Robert Garnick to Vice Presidents
25 May 1994	Genentech Extends Benefits Coverage to Same-Sex Domestic Partners
21 Apr 1994	Genentech Files Suit Against Centocor
15 Apr 1994	Genentech Reports 1994 First Quarter Results
11 Apr 1994	Pulmozyme Introduced in Ireland
04 Apr 1994	Genentech to Provide Growth Hormone Products Through PCS Pharmacy Network
04 Apr 1994	Pulmozyme Phase II Clinical Study Completed in Hospitalized Chronic Bronchitis Patients
08 Mar 1994	FDA Grants Genentech License to Market Nutropin for Growth Hormone Deficiency in Children
28 Feb 1994	Genentech Receives U.S. Patent for Transforming Growth Factor Beta (TGF)
11 Feb 1994	Genentech Begins Construction of $58 Million Laboratory Facility in South San Francisco
21 Jan 1994	Genentech Files Suit against Tanox Biosystems
19 Jan 1994	Settlement Reached in Factor VIII Litigation Involving Genentech, Miles, The Scripps Research Institute and Rhone-Poulenc Rorer
19 Jan 1994	Genentech Reports 1993 Fourth Quarter And Year End Results
07 Jan 1994	Pulmozyme Becomes Available to Cystic Fibrosis Patients
30 Dec 1993	FDA Grants Genentech License to Market Pulmozyme
18 Nov 1993	J. Beers Named General Manager of Genentech Canada, Inc.
17 Nov 1993	Genentech Receives FDA Approval to Market Nutropin for Growth Failure Due to Chronic Renal Insufficiency
25 Oct 1993	FDA Advisory Committee Unanimously Recommends Approval for Nutropin as Treatment for Growth Failure in Children with Chronic Renal Insufficiency
19 Oct 1993	Genentech Unveils $10 Million Program for High School Biology Teachers
14 Oct 1993	Genentech Reports Third Quarter Results
30 Sep 1993	Study Shows Alteplase t-PA Significantly Reduces Death Up To 12 Hours After Heart Attack Begins
03 Sep 1993	Activase Regains Marketshare
20 Aug 1993	STILE Study for Peripheral Arterial Occlusion Discontinued
09 Aug 1993	FDA Advisory Committee Unanimously Recommends Pulmozyme (DNase) for Approval as Cystic Fibrosis Treatment
29 Jul 1993	Genentech Granted Permanent Injunction in Wellcome Litigation Over t-PA Patents
14 Jul 1993	Genentech Reports Second Quarter Results
22 Jun 1993	Genentech Issued Pioneering Basic Processes Patent; Files Suit Against Lilly for Infringement
14 Jun 1993	Bio Holds First Board Meeting, Genentech CEO Elected Chairman
30 Apr 1993	41,000 Patient Gusto Trial Shows Activase t-PA Most Effective Clot-Buster to Save Lives of Heart Attack Patients
16 Apr 1993	Genentech Reports First Quarter Results
15 Apr 1993	Genentech Joins Coalition in Favor of Biodiversity Treaty
30 Mar 1993	Genentech Files Regulatory Applications to Market Pulmozyme (dornase alfa) DNase for Cystic Fibrosis in the United States, Canada, Europe
28 Mar 1993	Press Statement: Government-Imposed Price Controls Would Strangle Investment and Raise Health Care Costs
16 Mar 1993	Genentech Files Complaint with International Trade Commission to Enforce Growth Hormone Patents
03 Mar 1993	Genentech Announces Collaboration with GenVec to Develop Gene Therapy for Cystic Fibrosis
10 Feb 1993	Genentech French Patent Partially Revoked
20 Jan 1993	Genentech Reports Fourth Quarter and Year End Results
10 Dec 1992	Genentech Names Kurt Kopp to Head European Organization
09 Dec 1992	Genentech Receives U.S. Patent for Recombinant Human Nerve Growth Factor
02 Dec 1992	Pulmozyne(TM)(rhDNase) III Clinical Study Completed in Cystic Fibrosis
23 Oct 1992	Genentech Opens World's Largest Biotechnology Research Facility
15 Oct 1992	Genentech Reports Third Quarter Results
10 Sep 1992	Genentech Elects Linda Fayne Levinson To Board Of Directors
03 Sep 1992	Study Shows Altepase t-PA Significantly Reduces Mortality Up to 12 Hours After Heart Attack Begins
17 Jul 1992	Court Rules in Favor of Genentech in t-PA Patent Dispute
16 Jul 1992	Genentech Reports Second Quarter Results
15 Jul 1992	Xenova Receives Additional Equity Investment from Genentech, Inc.
08 Jun 1992	Genentech Secures European Patent for t-PA
14 Apr 1992	Genentech Reports First Quarter Results
31 Mar 1992	Genentech Names Gregory Baird Vice President of Corporate Communications
03 Mar 1992	Genentech Enters International Commercial Development and Marketing Agreement with Roche for DNase
16 Jan 1992	Genentech Reports Fourth Quarter and Year End Results
15 Jan 1992	Tularik Inc. Formed to Pursue Novel Biopharmaceutical Approach
10 Dec 1991	Wellcome and Sandoz Out-License Genentech Monoclonal Antibidody Patent
29 Oct 1991	Genentech Announces Auction of Vitamin C Concern
28 Oct 1991	Genentech Wins First Major Japanese Biotechnology Patent Case
16 Oct 1991	Genentech Announces Third Quarter Earnings
23 Sep 1991	Incyte And Genentech To Develop Drug For Treating Septic Shock
09 Sep 1991	Genentech and Xenova Announce New $20 Million Agreement
31 Jul 1991	Genentech Promotes Marty Glick to Vice President and Treasurer
17 Jul 1991	Genentech Reports Second Quarter Results
18 Jun 1991	Roche and Genentech Reach Agreement Over Human Growth Hormone Patent Dispute
06 Jun 1991	Genentech's t-PA Launched in Japan
18 Apr 1991	Genentech Announces First Quarter Results
05 Apr 1991	Genentech to Test Potential Therapy for Breast and Ovarian Cancers
21 Mar 1991	New gp120 AIDS Vaccine Enters NIAID Clinical Trials
03 Mar 1991	ISIS-3 Results Controversial and Inconclusive for U.S. Practice; T-PA Used in ISIS-3 Study Not Genentech's Product
28 Feb 1991	SmithKline to Stop Misleading ISIS-3 Ads
28 Feb 1991	Judge Requires Beecham To Abide By Court Promises Concerning ISIS-3 Ads
25 Feb 1991	Genentech Seeks Federal Court Order to Stop Beecham's False Advertising of Heart Attack Drugs
29 Jan 1991	FDA Grants Genentech Orphan Drug Status for DNase, a Potential Cystic Fibrosis Treatment
22 Jan 1991	Telios Pharmaceuticals and Genentech to Develop Anti-Clotting Drug
21 Jan 1991	Xenova and Genentech Expand Their Research and Development Collaboration
17 Jan 1991	Genentech Reports Fourth Quarter Earnings
07 Jan 1991	Genentech and Glycomed Announce Pact to Develop Carbohydrate-Based Therapeutics
21 Dec 1990	Genentech Granted Product License for Interferon Gamma-1B
21 Dec 1990	HHS News U.S. Department of Health and Human Services
17 Dec 1990	Genentech to Broadly License Key Monoclonal Antibody Patent
07 Dec 1990	Genentech Reaches an Agreement to Settle Class Action Litigation
27 Nov 1990	Study Begins to Test gp120 as a Potential Immune System Booster in HIV Infection
23 Oct 1990	Genentech Announces Third Quarter Results
12 Oct 1990	Genentech to Build $75 Million Research Center
20 Sep 1990	European Co-operative Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA)
07 Sep 1990	Genentech and Roche Merger Transaction Completed
31 Aug 1990	Roche and Genentech to Complete Merger Transaction On or About September 7
15 Aug 1990	Genentech and Abott Settle Litigation Over t-PA Patents
07 Aug 1990	Genentech Promotes Marty Glick to Treasurer
07 Aug 1990	Genentech Promotes Arthur D. Levinson to Vice President of Research
06 Aug 1990	Genentech and Roche Certify Substantial Compliance with FTC Request
13 Jul 1990	Genentech Reports Second Quarter Results
08 Jun 1990	Genentech Stockholders Approve Roche Agreement
06 Jun 1990	FDA Approves t-PA for Pulmonary Embolism
06 Jun 1990	Motion to Enjoin Vote at Genentech Stockholder Meeting Denied
01 Jun 1990	Genentech Research on Protection of Chimpanzees from HIV Infection to be Published
29 May 1990	Genentech Announces Potential Therapy for Cystic Fibrosis
23 May 1990	Genentech Receives Important Process Patent For Gamma Interferon
03 May 1990	Genentech Issues Proxy on Roche Merger; Annual Meeting Set for June 8
25 Apr 1990	Genentech Reports First Quarter Results
06 Apr 1990	Genentech Wins Key t-PA Patent Cases in U.S. Federal Court
29 Mar 1990	Roche-Genentech Transaction Passes Exon-Florio Review
23 Mar 1990	Federal Trade Commission Requests More Information on Genentech-Roche Merger
08 Mar 1990	New Trial Results Inconclusive for U.S. Practice; Role of Heparin in Gissi-2 Questioned
28 Feb 1990	Genentech Begins Clinical Trials of Relaxin
02 Feb 1990	Genentech and Roche Holding LTD Form Pioneering Relationship; Roche to Own 60 Percent of an Independent Genentech
29 Jan 1990	Physicians Choose Activase as Preferred Heart Attack Treatment for Themselves
18 Jan 1990	Biogen and Genentech Enter Into Cross-License Agreement for Gamma Interferon in The United States
18 Jan 1990	Revised Development Plans Announced for CD4-based Products, Potential AIDS Therapeutics
17 Jan 1990	Genentech Fourth Quarter Revenues Up 24 Percent; 1989 Revenues Top $400 Million
09 Jan 1990	Genentech Surpasses 1989 Product Sales Goals
03 Jan 1990	Genentech Acquires Full Ownership of Canadian Operation
02 Jan 1990	Genentech Files FDA Application to Market Gamma Interferon in The United States
12 Dec 1989	TGF-beta Patent Issued December 12, 1989
30 Nov 1989	Genentech Sponsors Programs for Pharmacists "Building A New Pharmacopeia" Premieres at ASHP
10 Nov 1989	Genentech Appoints Richard Brewer Vice President- Marketing
10 Nov 1989	Genentech Appoints Gary Lyons Vice President -- Business Development
30 Oct 1989	Competitors Merge Marketing Strength to Co-Promote t-PA, Blood-Clot-Dissolving Agent, in Germany
24 Oct 1989	Genentech Third Quarter Profits Higher
18 Sep 1989	Genentech Receives Third Patent for Gamma Interferon
14 Sep 1989	Genentech Begins Clinical Trials of Insulin-Like Growth Factor
30 Aug 1989	Genentech Awards First Scientific Fellowship to David Goeddel
29 Aug 1989	Genentech Appoints M. David MacFarlane Vice President -- Regulatory Affairs
21 Aug 1989	Genentech rCD4 Partnership Raises $72.5 Million
11 Aug 1989	Genentech Promotes Murphy and Adds Rogers to Public Relations Staff
01 Aug 1989	Genentech Receives Additional United States Patent for t-PA
18 Jul 1989	Genentech Reports Second Quarter Earnings
06 Jun 1989	Genentech Expands CD4 Clinical Trials for AIDS
24 May 1989	Genentech Appoints David Beier Vice President - Government Affairs
11 May 1989	Genentech Opens Corporate Day Care Center
19 Apr 1989	Genentech Reports First Quarter Earnings and Increase in Activase Sales
13 Apr 1989	Genentech Scientists Share 1989 Investor of the Year Award
21 Mar 1989	Cross-Licensing Agreement Reached on Factor VIII Genetically Engineered Clotting Agent for Hemopheliacs
27 Feb 1989	FDA Approves Reduced Mortality Claim for Heart Attack Drug
16 Feb 1989	Genentech Anounces Activase Co-Promotion Agreement
31 Jan 1989	Genentech Will Not Appeal British t-PA Patent Case
25 Jan 1989	Genentech Reports 1988 Financial Results
10 Jan 1989	Genentech Meets Sales Forecast and Announces Two Collaborative Agreements
09 Jan 1989	Genentech, Cal Bio Announce Neonatology Product Agreement
12 Dec 1988	Genentech Forecasts 1988 Results
08 Dec 1988	Ralph Snyderman, Genentech VP Named Chancellor at Duke University Medical School
09 Nov 1988	New Drug Application For t-PA Filed in Japan
31 Oct 1988	British Court of Appeals Rules in t-PA Patent Case
21 Oct 1988	Genentech Reports Results For Third Quarter
14 Oct 1988	Genentech Reports Shareholder Suits Filed
27 Sep 1988	Genentech Sees Quarterly Earnings Flat With Last Year
23 Aug 1988	Genentech Receives Second t-PA Patent in the United States
05 Aug 1988	Genentech Wins Growth Hormone Patent Suit
14 Jul 1988	Genentech Reports Increased Earnings, Sales in Second Quarter
05 Jul 1988	Axel Ullrich, Genentech Staff Scientist, Named Director of Max Planck Institute
23 Jun 1988	Free Heart Drug To Needy, Uninsured Patients
21 Jun 1988	Genentech Receives Broad t-PA Patent in the United States
11 May 1988	Genentech Appoints Two Vice Presidents
21 Apr 1988	Genentech Adopts Preferred Share Rights Purchase Plan
18 Apr 1988	Genentech Reports First Quarter Earnings
07 Apr 1988	Genentech Creates Foundation to Fund Basic Biotechnology Research
03 Mar 1988	Genentech Announces New VP of Sales
24 Feb 1988	Genentech Names Three Vice Presidents
24 Feb 1988	Genentech Stock to be Listed on NYSE March 2
22 Feb 1988	Genentech Elects New Director to Its Board
21 Jan 1988	Genentech Reports Significant Increase in 1987 Financial Results
11 Jan 1988	Genentech Announces Product Sales and NYSE Listing
13 Nov 1987	T-PA Approved in Canada
13 Nov 1987	Licensing of Activase Marks New Era in Treating Heart Attacks
03 Nov 1987	Genentech's Patent on Basic Recombinant DNA Technology Issues in The United States
02 Nov 1987	Genentech Reports Third Quarter Results
14 Oct 1987	Genentech Appoints Two Vice Presidents
13 Oct 1987	T-PA Approved in West Germany
31 Aug 1987	T-PA Approved in South Korea
24 Aug 1987	Genentech Files Patent Suit on t-PA
07 Aug 1987	T-PA Approved in Austria
21 Jul 1987	Genentech Reports Second Quarter Results
07 Jul 1987	Britain's High Court Rules on t-PA Patent Dispute
01 Jul 1987	Mitsubishi Chemical Industries and Genentech Agree to Commercialize Research Products
11 Jun 1987	T-PA Approved in France
29 May 1987	FDA Committee Reviews Activase t-PA
24 Apr 1987	Genentech Reports First Quarter Results
01 Apr 1987	FDA Cardiorenal Advisory Committee to Review t-PA
12 Mar 1987	Genentech Completes Sale of $150 Million Convertable Subordonated Debentures in Europe
06 Mar 1987	Genentech Files Lawsuit Against FDA for Legalization of Orphan Drug Standards for Human Growth Hormone
21 Jan 1987	Genentech Reports Substantial Increase in 1986 Financial Results
19 Jan 1987	Progress on Genentech t-PA Patent Application in Japan
05 Jan 1987	Genentech Completes Early Buyout Or First Two R&D Partnerships
30 Dec 1986	Genentech Partnership Purchases Recieve Majority Approval
15 Dec 1986	Genentech Names Chief Financial Officer
27 Oct 1986	Genentech Proposes Early Partnership Buyout
16 Oct 1986	Genentech Reports Third Quarter Results
12 Sep 1986	Genentech To Defend Patent Suit
04 Aug 1986	Genentech Elects New Director to Its Board
04 Aug 1986	Genentech Names Four Vice Presidents
23 Jul 1986	Genentech Reports Second Quarter Results
25 Apr 1986	Genentech Reports First Quarter Results
26 Feb 1986	Genentech's T-PA Patent Issues in the United Kingdom Today Suit Against Wellcome Follow
12 Feb 1986	Genentech Reports Substantial Increase in 1985 Revenues and Income
21 Jan 1986	Genentech Announces 2 For 1 Stock Split
17 Dec 1985	Genentech Awarded Orphan Drug Status For Growth Hormone
12 Nov 1985	Business Venture Formed for Vitamin C Process Development
24 Oct 1985	Genentech Reports Third Quarter Results
18 Oct 1985	FDA Approves Genentech's Drug to Treat Children's Growth Disorder
30 Jul 1985	Genentech Reports Second Quarter Results
16 Jul 1985	Recombinant DNA Technology
14 Jun 1985	Genentech and Major European Pharmaceutical Firm Announce Institute for Cancer Research
24 Apr 1985	Genentech Reports First Quarter Results
22 Apr 1985	Genentechs Answer to Pituitary Derived Growth Hormone: Recombinant DNA Technology
26 Mar 1985	Susan Atkins Joins Genentech
21 Mar 1985	Genentech Forms Canadian Marketing Joint Venture With Major Pharmaceutical Company
15 Mar 1985	Genentech Offers 1 Million Of Common Stock At $45 Per Share
28 Feb 1985	Genentech Plans To File For Public Offering
14 Feb 1985	Genentech Reports Substantial Increase in 1984 Revenues and Income
14 Jan 1985	Media Advisory
02 Jan 1985	Genentech Clinical Partners III Raises $30.7 Million For The Development Of TNF
30 Oct 1984	Genentech Reports Third Quarter Results
14 Sep 1984	Genentech Reports on Meeting with FDA Advisory Committee
11 Sep 1984	Cutter To Receive Factor VIII License From Genentech
19 Jul 1984	Genentech, Inc. Reports Second Quarter Results
06 Jun 1984	Promising New Anti-Cancer Drug Produced By Genentech
23 Apr 1984	Genentech Expands Its Patent Department
19 Apr 1984	Genentech Reports First Quarter Results
13 Mar 1984	King of Sweden Presents Genentech President with Membership in Royal Swedish Academy
21 Feb 1984	Genentech Has Begun Human Evaluation of t-PA in Heart Attack Victims
15 Feb 1984	Genentech Reports Significant Increase in 1983 Revenues and Income
10 Jan 1984	Genentech President Gives Stock Analysts Preview Of 1983 Results and Beyond
05 Jan 1984	Travenol And Genentech Sign Definitive Agreement To Form Diagnostics Joint Venture
20 Dec 1983	Genentech Begins Human Evaluation of Human Gamma Interferon
15 Dec 1983	Genentech and Major European Pharmaceutical Firm Announce Commercialization Agreement on T-PA
01 Dec 1983	Travenol and Genentech to Form Diagnostics Joint Venture
14 Nov 1983	Dr. Goeddel Of Genentech Receives Prestigious Eli Lilly Award
10 Nov 1983	Media Advisory
20 Oct 1983	Genentech Reports Third Quarter Results
19 Aug 1983	Genentech, Inc. and Granada Announce bovine interferon R&D Agreement
09 Aug 1983	Genentech Reports Second Quarter Results
22 Jul 1983	Hewlett-Packard and Genentech Form Joint Venture
29 Jun 1983	Genentech Clinical Partners II Raises $34 Million for The Development of t-PA
24 May 1983	Possible Collaboration Between Genentech And Hewlett-Packard
10 May 1983	Genentech Obtains Exclusive Development Rights on T-PA
05 May 1983	Genentech Appoints Four Vice Presidents
29 Apr 1983	Genetech Plans to Form New R&D Partnership for TPA Development
29 Apr 1983	Genentech Reports First Quarter Results
17 Feb 1983	Genentech 1982 Revenues and Net Income Up; Company Announces 3 For 2 Stock Split
02 Nov 1982	Genentech Reports Third Quarter Results
29 Oct 1982	First Recombinant DNA Product Approved By The Food And Drug Administration
22 Oct 1982	Genentech Elects Two New Directors to Its Board
20 Oct 1982	Swedish Group Invests $20 Million in Genentech
19 Oct 1982	Genentech Plans to Meet Year-End Goals Despite a Third Quarter Loss
13 Oct 1982	Genentech Establishes New Research Partnership
16 Sep 1982	Geneticist Martin To Join Genentech as Vice President of Research
27 Aug 1982	Genentech Announces New Vice-President
25 Aug 1982	Genentech Announces Possible Research And Development Partnership
27 Jul 1982	Genentech Reports Second Quarter Results
23 Jul 1982	(TPA) Produced By Recombinant DNA Techniques
22 Jun 1982	Genentech, Inc. Contracts With Two Japanese Companies to Develop New Thrombolytic Agent
17 May 1982	Mitsubishi Chemical Industries, Ltd. And Genentech, Inc. To Develop Human Albumin For Commercial Production
29 Apr 1982	Genentech, Inc. Reports Results For First Quarter, 1982
13 Apr 1982	Corning Glass, Genentech to Form Industrial Enzyme Company
08 Mar 1982	Genentech Scientists Develop Bovine Interferon
18 Feb 1982	Genentech Revenues Up 137% Net Income Up Slightly
06 Jan 1982	Genentech Acquires Site For Future Facilities Expansion in South San Francisco
24 Nov 1981	Human Serum Albumin Produced By Recombinant DNA
31 Oct 1981	Genentech, Inc. Reports Third Quarterly Results
30 Oct 1981	Five Genentech Products Receive NIH Approval for Large Scale Production
22 Oct 1981	The first successful expression of immune interferon by recombinant DNA
21 Oct 1981	David Packard Elected to Board of Directors of Genentech
29 Sep 1981	Genentech is Beginning Efficacy Studies with Human Growth Hormone in Children with Hypopituitarism
21 Sep 1981	First Major Investment by Japanese Interests in Genentech
03 Aug 1981	Genentech, Inc. Reports Second Quarter Results
01 May 1981	Genentech, Inc., Reports First Quarter Revenues of $3.9 Million in 1981 vs. $1.6 Million in 1980
18 Feb 1981	Genentech Reports Annual Revenues of $9.0 Million in 1980 Vs. $3.4 Million in 1979
12 Jan 1981	FDA-Approved Clinical Tests on Humans Begin Today With Human Growth Hormone Made by Recombinant DNA
08 Jan 1981	Flour Purchases Shares in Genentech
19 Aug 1980	Genentech Files Registration Statement With SEC For Its Initial Public Offering
04 Jun 1980	Genentech Announces Successful Production and Preliminary Biological Tests For Fibroblast and Leukocyte Interferon
01 Jan 1980	Supreme Court Decision Will Spur Genetics Industry
11 Jul 1979	First Successful Bacterial Production of Human Growth Hormone Announced
06 Sep 1978	First Successful Laboratory Production of Human Insulin Announced

Our Pipeline

Our pipeline includes new molecular entities that address serious unmet medical needs.

Approvals Timeline

A look at our approvals past and present.

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Press Releases

Helpful Resources

Our Pipeline

Approvals Timeline